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Abstract
The objective of these studies was to evaluate possible airway inflammation and
remodeling at the bronchial level in cross-country skiers without a prior diagnosis of
asthma, and relate the findings to patients with mild chronic asthma and patients with
newly diagnosed asthma. We also studied the association of airway inflammatory changes
and bronchial hyperresponsivess (BHR), and treatment effects in cross-country skiers and
in patients with newly diagnosed asthma. Differences were also studied in airway
inflammation between atopic and nonatopic asthmatics.
Bronchial biopsies were obtained from the subjects by flexible bronchoscopy, and the
inflammatory cells (eosinophils, mast cells, T-lymphocytes, macrophages, and
neutrophils) were identified by immunohistochemistry. Tenascin (Tn) immunoreactivity in
the bronchial basement membrane (BM) was identified by immunofluorescence staining.
Cell densities were counted and the thickness of Tn immunoreactivity was measured.
Lung function was measured with spirometry, and BHR was assessed by methacholine
(skiers) or histamine (asthmatics) challenges. Skiers with BHR and asthma-like symptoms
were recruited to a drug-intervention study. Skiers were given treatment with placebo or
budesonide (400 µg bid), and bronchial biopsies were obtained after 22 weeks’ treatment.
Patients with newly diagnosed asthma were given treatment for 16 weeks with placebo,
salmeterol (SLM) (50 µg bid), fluticasone propionate (FP) (250 µg bid), or disodium
cromoglicate (DSCG) (5 mg qid). Bronchial biopsies were obtained at baseline and at the
end of the treatment period.
In the skiers a distinct airway inflammation was evident. In their bronchial biopsy
specimens, T-lymphocyte, macrophage, and eosinophil counts were, respectively greater
by 43-fold (P<0.001), 26-fold (P<0.001, and 2-fold (P<0.001) in skiers, and by 70-fold
(p>0.001), 63-fold (P<0.001), and 8-fold (P<0.001) in asthmatic subjects than in controls.
In skiers, neutrophil counts were more than 2-fold greater than in asthmatic subjects
(P<0.05). Tn expression was higher in skiers vs. controls and lower in skiers vs. mild
asthmatics. There were no significant changes between hyperresponsive and
nonhyperresponsive skier in the inflammatory cell counts or Tn expression. Treatment
with inhaled budesonide did not attenuate asthma-like symptoms, the inflammatory cell
infiltration, or basement membrane tenascin expression in the skiers.
In newly diagnosed asthmatic patients, SLM, FP, and DSCG reduced asthma
symptoms, and need for rescue medication (P<0.04). BHR was reduced by doubling doses
2.78, 5.22, and 1.35 respectively (all P<0.05). SLM and placebo had no effect on cell
counts or Tn expression. FP and DSCG reduced eosinophil counts in the bronchial biopsy
specimens (P<0.02 and <0.048, respectively). No significant change in tenascin
expression appeared in any treatment group.
Regarding to atopy, no significant differences existed in the inflammatory cell counts
in the bronchial mucosa of subjects with newly diagnosed asthma or in elite cross country
skiers. Tn expression in the BM was significantly higher in atopic asthma than in those
with nonatopic asthma.
Airway inflammation occurred in elite cross-country skiers with and without
respiratory symptoms or BHR. Their inflammatory cell pattern differed from that in
asthma. Infiltration with eosinophils, macrophages, and mast cells was milder, but
lymphocyte counts did not differ from counts in asthmatic airways. Neutrophilic
infiltration was more extensive in skiers than in asthmatics. Remodeling took place in the
skiers’ airways, as reflected by increased expression of BM tenascin These inflammatory
changes and Tn expression may be caused by prolonged exposure of the lower airways to
inadequately humidified cold air.
Inflammatory changes and remodeling were not reversed with anti-inflammatory
treatment. In contrast, in patients with newly diagnosed asthma, anti-inflammatory
treatment did attenuate eosinophilic inflammation in the bronchial mucosa. In skiers, anti-
inflammatory treatment did not attenuate BHR as it did in asthmatic patients. The BHR in
skiers was attenuated spontaneously during placebo treatment, with no difference from
budesonide treatment. Lower training intensity during the treatment period may explain
this spontaneous decrease in BHR. The origin of BHR probably differs in skiers and in
asthmatics. No significant association between BHR and inflammatory cell counts or
between BHR and Tn expression was evident in cross-country skiers or asthmatic
subjects. Airway remodeling differed between atopic and nonatopic asthma. As opposed
to nonatopic asthma, Tn expression was higher in atopic asthma and is related to
inflammatory cell densities.
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Abbreviations
ASM airway smooth muscle
BAL bronchoalveolar lavage
bid twice daily
BHR bronchial hyperresponsiveness
BM basement membrane
CI confidence intervals
DD doubling dose units
DSCG disodium cromglycate
EIA exercise-induced asthma
EIB exercise-induced bronchoconstriction
ECP eosinophil cationic protein
ECM extracellular matrix
EPO eosinophil peroxidase
EVH eucapnic hyperventilation
FEV1 forced expiratory volume in one second
FP fluticasone propionate
FVC forced vital capacity
IGE immunoglobulin E
IL interleukin
IQr interquartal range
mAb monoclonal antibody
PC20FEV1 provocative consentration inducing a 20% fall in FEV1
PD15FEV1 provocative dose inducing a fall of 15% in FEV1
PEF peak flow
PL placebo
pMDI pressurised metered dose inhaler
qid four times daily
SLM salmeterol
Tn tenascin
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1 Introduction and review of the litterature
1.1 Definitions of asthma and bronchial hyperresponsiveness
Asthma is a disease with many clinical phenotypes. An international consensus definition
for asthma has been developed to characterize asthma (www.ginasthma.com), the main
characteristics of which are reversible airflow obstruction and hyperresponsiveness of the
airways to various stimuli.  Intermittent airflow obstruction leads to one of the main
clinical symptoms of asthma: attacks of breathlessness; cough, excessive mucus secretion,
and wheeze are some others. Distinct morphological changes are visble in the asthmatic
bronchial mucosa. Infiltration of inflammatory cells increases, especially eosinophils and
T-lymphocytes in the submucosa and the epithelium. Thickening of the epithelial
basement membrane (BM) occurs even in mild asthma. Epithelial integrity is lost due to
epithelial shedding, and the number of mucus-secreting goblet cells rises.  Edema results
from leakage of plasma from the microvasculature. Airway remodeling is also an
important characteristic of asthma. (Bateman et al 2008)
Bronchial hyperresponsiveness (BHR), a major pathophysiological feature of asthma,
is an abnormal tendency of the bronchi to contract following the exposure to a variety of
stimuli, including allergens, cold air, exercise, and non-physiological stimuli. However,
BHR is not specific for asthma. Even 70% of subjects with BHR report no respiratory
symptoms (Kolnaar et al 1997). Asymptomatic BHR, however, is a risk factor for asthma
(Hopp et al 1990, Laprise and Boulet 1997), and degree of BHR may predict the outcome
of asthma (Gerritsen et al 1989). Patients with various lung disorders like chronic
obstructive pulmonary disease (COPD), tuberculosis, bronchiectases, or farmer’s lung can
also present with BHR (Tashkin et al 1992, Laitinen et al 1974, Varpela et al 1978,
Mönkäre et al 1981). Viral infections can also cause a transient BHR in nonasthmatic
subjects (Empey et al 1976, Laitinen et al 1980).
BHR is measured by challenging airways to bronchoconstrictive stimuli that induce
airflow limitation directly or indirectly.  Direct stimuli act on effector cells such as smooth
muscle cells, causing bronchoconstriction. The most frequently used agents in BHR
testing in research and clinical settings are methacholine and histamine, which are direct
stimuli (Foos 2003). Indirect stimuli cause bronchoconstriction by acting on other than
effector cells, the so-called intermediary cells, by releasing inflammatory mediators, or by
stimulating neural pathways (Van Schoor et al 2005). Indirect stimuli can be
pharmacological, such as adenosine, or they can be physiological, such as exercise. In
asthmatic subjects, the degree of BHR is clearly much more pronounced than in
nonasthmatic subjects (Sovijärvi et al 1993), and asthmatic subjects are at least 1000 times
more sensitive to bronchoconstricting stimuli. The magnitude of BHR to histamine or
methacholine correlates with other signs of asthma like the degree of diurnal variation of
Peak Flow (PEF) (Ryan et al 1982, Gibson et al 1995).
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1.2 Airway inflammation and remodeling in asthma
The inflammatory character of asthma has been recognized since the 1990s. Earlier, the
airway obstruction was considered to be caused by contraction of smooth muscle and by
mucus secretion. Introduction of flexible bronchoscopy gave new insights into the disease
pathology (Diamant et al 2007), and made it possible to investigate larger patient
populations and study the complex inflammatory reaction at the bronchial wall level.
Bronchial biopsy remains the standard investigative method to determine inflammation
and remodeling in the airways (Jeffery et al 2000). As flexible bronchoscopy is an
invasive method – though mostly well tolerated by asthmatics (Busse et al 2005) – new
non-invasive techniques have been developed to study inflammation and remodeling in
asthma such as induced sputum and exhaled breath condensate. These methods make it
possible to study a greater number of subjects, but for studying inflammatory alterations in
the airway wall, samples acquired by these methods cannot totally replace endobronchial
biopsies (Bergeron et al 2007).
Remodeling occurs in a wide range of tissues and organs and reflects the healing
response to an injury (Bergeron et al 2007). Airway remodeling describes the structural
changes in the airway wall that develop in response, by repair and restoration, to a chronic
inflammatory process in asthmatic airways. Remodeling in asthma includes inflammatory
cell infiltration in the submucosa, destruction of the epithelium, thickening of the
basement membrane (BM) and changes in the extracellular matrix, hypertrophy and
hyperplasia of smooth muscle, increased vascularity, mucus metaplasia, and the promotion
of a cholinergic phenotype in the airway nerves (Beckett and Howarth 2003, Durcan et al
2006). Acute inflammation usually resolves without any pathologic changes remaining in
the structures, but when inflammation does not resolve, remodeling is unavoidable
(McParland et al 2003).
Evidence is extensive for chronic inflammatory cell infiltration in the bronchial
mucosa (Lundgren et al 1988, Beasley et al 1989, Jeffery et al 1989, Ohashi et 1992,
Bentley et al 1992, Ackerman et al 1994). Inflammatory cell infiltration occurs in both
chronic (Laitinen et al 1997) and newly diagnosed asthma (Laitinen et al 1993a).
Compared with control subjects, patients with newly diagnosed and chronic asthma show
an increased number of eosinophils, lymphocytes, macrophages, and mast cells in the
bronchial mucosa of (Jeffery et al 1989, Foresi et al 1990, Bentley et al 1992, Laitinen et
al 1997, Hoshino et al 1998a). Neutrophilic inflammation occurs principally in severe
asthma (Wentzel et al 1999). Inflammatory cell infiltration in the bronchial mucosa is seen
also in patients with asthma in clinical remission of asthma (Foresi et al 1990), but
inflammatory cell counts decrease after treatment with inhaled corticosteroids and this is
accompanied by improvement in lung function and a reduction in asthma symptoms
(Laitinen et al 1992, Djukanovi? et al 1992, Trigg et al 1994, Laitinen et al 1997).
The epithelium in the airways forms an outer cellular barrier and is in the front line of
defense against triggers of asthma like aeroallergens or viral infections. It is therefore not
surprising that it is altered in asthma. Bronchial biopsies from asthmatic patients show
extensive epithelial damage consisting of epithelial shedding (Dunnill 1960, Laitinen et al
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1985, Jeffery et al 1989, Laitinen et al 1993a). Such epithelial damage may be caused by
proteases and granule products released by eosinophils and mast cells (Motojima et al
1989, Pesci et al 1993, Venaille et al 1995). Numbers of ciliated cells decrease, and of
goblet cells increase (Laitinen et al 1993a). The shed columnar epithelial cells are quickly
replaced by basal cells (Erjefält et al 1997), but the barrier structure is still weak, and
intraepithelial nerves can be more exposed to stimuli than in a normal intact epithelium
(Laitinen et al 1985). Epithelial denudation may be due to the trauma caused by biopsy
forceps (Söderberg et al 1990, Ordoñez et al 2000a). This theory is not supported by the
studies performed with a rigid bronchoscope, which yields representative biopsy
specimens with proper airway epithelium (Laitinen et al 1985, Laitinen et al 1993a).
Epithelial shedding is evident even in mild asthma (Lozewicz et al 1990).
Why the epithelium in asthmatic airways is fragile is still unclear. The attachment of
the epithelium to the inner epithelial wall may be defective. In an electron microscopic
study, Ohashi et al (1992) showed widening of intercellular spaces and tight junctions in
the bronchial epithelium of asthmatic subjects as a possible mechanism of epithelial
shedding and BHR. Epithelial cells can be injured by mediators released by inflammatory
cells, or they can be denuded from the underlying BM due to a repair process. It is also
possible that the cells undergo apoptosis (Vignola et al 2000), but the airway epithelial
cells in asthmatic subjects possess antiapoptotic properties (Vignola et al 2001). The
bronchial epithelial cell is not a passive element. Epithelial cells communicate with the
submucosal matrix to promote the normal epithelial repair, but in asthma this function is
abnormal (Holgate 2007). Epithelium plays an active role in the repair process and is a
source of growth factors like epidermal growth factor (EGFR) and transforming growth
factor ? (TGF?), which are more intensively expressed in the epithelium of asthmatic
subjects than in that of control subjects (Vignola et al 1997, Amishima et al 1998,
Redington et al 1998, Fedorov et al 2005). The bronchial epithelium secretes various
mediators of inflammation as response to epithelial injury and orchestrates the remodeling
process in the airway mucosa (Holgate 2007). Epithelial damage and inflammatory
reactions in the epithelium and submucosa may be considered as an airway wound-repair
process. With anti-inflammatory treatment, the damaged epithelium and inflammation in
the submucosa may be totally restored (Laitinen et al 1992).
In asthma, the epithelial repair process is altered and probably causes the subepithelial
fibrosis and thickening of the BM seen in asthma (Roche et al 1989, Chetta 1997, Ward
2002).  Reports are conflicting concerning the degree of BM thickening as correlated with
asthma severity, deterioration of lung function, and submucosal inflammatory cell
infiltration. Chetta and coworkers found that BM thickness correlated positively with
asthma symptoms and daily peak expiratory flow (PEF) variability and correlated
negatively with baseline lung function (Chetta et al 1997). In a recent study, BM thickness
was greater in patients with severe asthma than in those with mild asthma (Bourdin et al
2007). Other studies have found no correlation between BM thickness and lung function,
sex, age, or asthma duration (Payne et al 2003, Kim et al 2007). BM thickening occurs
even in children with asthma (Cokugras et al 2001, Payne et al 2003, Kim et al 2007). The
association of BM thickening and inflammation is obscure. In recent reports number of
eosinophils in the submucosa of asthmatic bronchi did not correlate with BM thickness
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(Fedorov et al 2005, Kim et al 2007). In another study, BM thickness correlated
significantly with the percentage of mast cells in the BAL fluid (Ward et al 2002).
Bronchial epithelium may be altered by physical exercise. In mice, intensive training
reduced the quantity of ciliated epithelial cells and induced apoptosis of bronchial
epithelial cells (Chimenti et al 2007). It is possible that similar epithelial damage is caused
by intensive training in humans. In long-distance runners the number of apoptotic
bronchial epithelial cells in induced sputum after the race was increased (Bonsignore et al
2006).
The extracellular matrix (ECM) in epithelial tissues consists of the BM and the loose
connective tissue that lies beneath the bronchial BM. The ECM is made up of
macromolecules that form an intricate network providing mechanical support for airway
structure. It is not only an inert framework in the airway wall but also an active regulator
of the functions of cells embedded in the ECM, e.g. differentiation, migration,
proliferation, and survival (Ingber et al 1994). The BM is a thin layer of specialized ECM,
composed of a basal lamina and the lamina fibroreticularis (Merker 1994). Its border at the
epithelial side can be seen clearly, but at the stromal side, a gradual change to the stromal
matrix makes it difficult to determine its inner border. The main components of BMs are
type IV collagen, laminin, nidogen, and proteoglycans (Merker et al. 1994). Changes in
the BM are mainly described in the lamina fibroreticularis (Roche et al 1989, Jeffery et al
1992), but changes are seen also in the components of the basal lamina. In a morphometric
study, Altraja and coworkers showed expression of laminin?2 and laminin?2 chains in
adult asthma. These chains are expressed only during lung morphogenesis (Virtanen et al
1996), and their reappearance in asthma may be the result of airway inflammation and
may reflect remodeling (Altraja et al 1996a). The increased thickness of the lamina
fibroreticularis in asthma is mainly caused by excess deposition of several ECM proteins
like proteoglycans tenascin (Tn) (Laitinen et al 1997), lumican, byglycan, and vesican
(Huang et al 1999) and of collagens (Roche et al 1989, Jeffery et al 1992).
One hallmark of this remodeling is the increase in bronchial smooth muscle mass.
Enlargement of smooth muscle mass consists of hypertrophy (Carroll et al 1993) or
hyperplasia (Cohen et al 1997). Because contraction of airway smooth muscle (ASM) is
largely responsible for the acute airway narrowing seen in asthma, ASM may play an
important role in BHR. In animal experiments, repeated challenge to an allergen causes a
marked increase in ASM mass (Sapienza et al 1991, Ramos-Barbón et al 2005),
suggesting that in ASM inflammation induces structural changes. ASM has also been
shown to increase in association with asthma severity: Greater smooth muscle mass is
evident in severe asthma than in moderate asthma (Pepe et al 2005).  Airway remodeling
with thickened BM and deposition of ECM proteins, and an increased ASM mass along
with vascular hyperplasia, mucosal edema, and mucus hypersecretion is the main reason
for the chronic airflow obstruction in asthma (Becket and Howarth 2003).
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1.2.1. Inflammatory cells
The eosinophil is the key effector cell in asthma, and eosinophilic inflammation in
asthmatic airways correlates with asthma severity (Bousquet el al 1990). Airway
eosinophilia is detectable in most asthma patients, but a non-eosinophilic phenotype of
asthma is known (Lemiére et al 2006). Eosinophils are present early in the airways even
before the diagnosis of asthma (Pohunek et al 2005). Airway eosinophilia is not a unique
feature of asthma, but also occurs in other diseases of the airways such as in chronic
bronchitis (Lacoste et al 1993). Eosinophils are recruited to the airway mucosa from the
circulation (Wardlaw 1999) by several chemokines like RANTES (Alam et al 1993) and
eotaxins (Garcia-Zepeda et al 1996). Eosinophils contain dense intracellular granules
filled with cytotoxic, eosinophil-specific granule proteins (ESGP): eosinophil cationic
protein (ECP), eosinophil peroxidase (EPO), eosinophil protein-X (EPX), and major basic
protein (MBP) (Venge et al 1988). By releasing these proteins into the airway mucosa,
eosinophils can cause extensive damage in the bronchial epithelium (Gleich et al 1988)
and start the injury-repair process leading to remodeling. In addition to the direct cytotoxic
effects of ESGPs, eosinophils also induce apoptosis of the bronchial epithelial cells
(Trautmann et al 2002). Interestingly, Wenzel et al (1999) found that in patients with
severe asthma, the subgroup of patients without airway eosinophilia had a thinner BM
than did patients with airway eosinophilia.
Eosinophils play an important role in neural remodeling by releasing EPO, MBP,
eosinophil-derived neurotoxin (EDN), and nerve growth factor (NGF), which is a member
of the neurotrophin family. Eosinophils localized to cholinergic nerves promote the action
of cholinergic nerves in the airways by increased expression of the muscarinic type 2
receptor and enhanced action of acetylcholine (Durcan et al 2006).
Eosinophils modulate their own accumulation and survival in tissues by expressing
cell-surface receptors and at the same time secreting activators of these receptors that are
important to their own activation, recruitment, and survival. Eosinophils secrete several
mediators of inflammation like cytokines (several interleukins and eotaxins), growth
factors like granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming
growth factor-beta (TGF-ß) and, cysteinyl leukotrienes (Jacobsen et al 2007). With these
mediators, eosinophils not only regulate their own existence and function but also
influence the function and survival of resident tissue cells (epithelial cells, fibroblasts,
smooth muscle cells) and inflammatory cells (T-lymphocytes, mast cells, dendritic cells,
neutrophils, and macrophages). However, eosinophils are not self-sufficient; they are also
regulated by other cells in the same environment, like T-lymphocytes, for their initial
recruitment to sites of inflammation (Jacobsen et al 2007).
Mast cells  are normal resident cells in the airways; they arise in the bone marrow and
travel to the airways. They contain granules filled with histamine, proteolytic enzymes
(tryptase, chymase), proteoglycans, cytokines ( IL-4, IL-5, IL-13), and lipid mediators
(leukotriene C4, prostaglandin D2) (Warner and Kroegel 1994). Mast cells have receptors
in their cell surface, and the activation of these receptors causes mast cells to become
partly or totally degranulated (Pesci et al 1993). In asthma, the number of mast cells may
be increased, especially in the airway epithelium, but the main difference from
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nonasthmatics is a greater degree of mast cell degranulation (Bradley et al 1991, Laitinen
et al 1993a, Pesci et al 1993). Degranulation is related to disease severity (Carroll et al
2002a) and to mucus secretion (Carroll et al 2002b). Allergen challenge causes a rapid
degranulation of the mast cells by activating the high-affinity receptor for immunoglobulin
E (Fc?RI) on the cell surface (Warner and Kroegel 1994). Mast-cell derived products act
as the main factors in the acute response to allergen by causing bronchoconstriction and
mucosal edema (Wenzel et al 1991, Bradding et al 2006). Mast cell infiltration in the
bronchial smooth muscle occurs in symptomatic asthmatic in BHR subjects but not in
subjects with eosinophilic bronchitis with chronic cough or in normal controls, suggesting
that in asthma, mast cells may be a key factor in BHR and in the development of variable
airflow obstruction (Brightling et al 2002, Begueret et al 2007). However, in one recent
study, neither an increase nor significant differences appeared in mast cell densities in the
airway smooth muscle between asthmatic subjects with BHR and control subjects or
subjects with chronic obstructive pulmonary disease (COPD) (Liesker et al 2007).
Furthermore, in contrary to findings by Brightling et al (2002), there was no correlation
between mast cell density and BHR to adenosine monophosphate (Liesker et al 2007).
Lymphocytes play a crucial role in asthma pathogenesis. In the asthmatic airway
mucosa, numbers of T-lymphocytes are increased (Azzawi et al 1990, Bentley et al 1992,
Poston et al 1992, Laitinen et al 1993 a, Ohashi et al 1998). T-lymphocytes are divided
into two major groups by the receptors they bear: CD4+ and CD8+ lymphocytes. In
asthma, the majority of T-lymphocytes bear a CD4+ cell surface antigen and are thus
called helper T-cells. CD4+ cells are divided into TH1- and TH2types, the TH2type being
predominant (Corrigan et al 1995).  T-lymphocytes play a regulatory role in asthmatic
airway inflammation. They orchestrate the inflammatory process by releasing cytokines,
particularly IL-4 and IL-5, leading to accumulation of eosinophils and mast-cell activation
in the bronchial mucosa (Bradley et al 1991, Durham et al 2000). Lymphocytes may also
participate in airway remodeling by interacting with airway smooth muscle, leading to
hypertrophy, at least in atopic asthma (Ramos-Barbon et al 2005, Begueret et al 2007).
Macrophages are the most prevalent cells in the bronchoalveolar space in both
asthmatic and nonasthmatic subjects (Beasley et al 1989). They are present also in the
asthmatic airway wall (Bentley et al 1992, Poston et al 1992, Laitinen et al 1993, Ohashi
et al 1998) and may be involved in asthma pathogenesis. Macrophages may also be
involved in the remodeling process of asthma by secreting growth factors and
proinflammatory cytokines including IL-1, TNF-?, IL-6, interferon ?, and GM-CSF (John
et al 1998, Hamid et al 2003). Some of these cytokines may prolong eosinophil survival.
Macrophages may also perpetuate mast cell activation in asthma and the late-phase
response to allergens (Hamid et al 2003). Alveolar macrophages in asthmatics release
TGF-?, suggesting that macrophages take part in airway remodeling (Vignola et al 1996).
Neutrophils. The role of neutrophils in asthma is still unclear. Neutrophils are
polymorphonuclear granulocytes with the potential to cause damage in tissues when
activated by releasing enzymes like neutrophil elastase, reactive oxygen compounds,
cytokines, and lipid mediators. The number of neutrophils in the bronchial mucosa is not
pronounced in clinically stable asthma (Poston et al 1992), but, in severe asthma,
neutrophils seem to play an important role (Kamath et al 2005). Neutrophil concentration
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in the bronchoalveolar lavage fluid and neutrophil numbers in endobronchial biopsies are
higher in patients with severe asthma than in patients with moderate asthma (Wenzel et al
1997). Neutrophils are increased also in patients with nocturnal asthma (Martin et al 1991)
and in acute severe asthma (Ordonez et al 2000b, Qiu et al 2007) as well as in
occupational asthma (Park et al 1998). In sudden-onset fatal asthma, neutrophilic
infiltration in the airway submucosa was significantly increased over that with slow-onset
fatal asthma (Sur et al 1993).
1.2.2 Tenascin in the bronchial basement membrane zone
Tenascin is a family of oligometric glycoproteins of the ECM that have adhesive and
antiadhesive properties. Tns include the isoforms Tn-C, Tn-N, Tn-R, Tn-X, Tn-Y, and Tn-
W, and they are first expressed during embryonic development, particularly in neural
development, skeletogenesis, and vasculogenesis (Jones and Jones 2000). Tns are
reexpressed in the adult during normal processes like wound healing (Mackie et al 1988)
and nerve regeneration (Probstmeier et al 2000) and in pathological states including
tumorgenesis and metastasis (Juuti et al 2004, Orend and Chiquet-Ehrismann 2006). In
breast cancer tumors, expression of tenascin expression is associated with a significantly
worse prognosis than for tenascin-negative cancers (Ioachim et al 2002).   Tns play an
important role in the developing embryo, and in the adult when remodeling processes
occur, but their specific functions still remain poorly understood. Tns play a regulatory
role, and they are involved in modulation of cell-matrix interactions and mediation of
matrix attachment to the environment (Hsia and Schwarzbauer 2005). Tn knock-out mice
were originally thought to develop normally (Saga et al 1992), but in further studies have
shown subtle abnormalities in wound healing, brain chemistry, and in the neuromuscular
junction, as well as in behavior (Mackie and Tucker 1999).
In the lung, Tn is normally expressed during embryonic development of the
conducting airway and alveoli and may participate in epithelial-mesenchymal interaction
during organogenesis of the lung (Zhao 1999, Kaarteenaho-Wiik 2001). Tn expression in
the adult lung has been described in several pathological states like pulmonary fibrosis
(Pääkkö et al 2000), sarcoidosis, atypical mycobacteriosis, and tuberculosis of the lung
(Kaarteenaho-Wiik 2007). In asthmatic subjects, increased Tn expression is apparent in
the bronchial BM in patients with chronic asthma, in patients with seasonal asthma
(Laitinen et al 1997, Hoshino et al 1998a), and in those with occupational asthma
(Laitinen et al 1996). In a placebo-controlled study, anti-inflammatory treatment with the
inhaled corticosteroid budesonide was shown in asthma patients to reduce the BM
accumulation of Tn. Simultaneously there occurs a significant reduction of number of T-
lymphocytes in the bronchial mucosa in budesonide-treated asthmatics, suggesting that in
asthma, Tn is associated with disease activity and airway inflammation (Laitinen et al
1997). However, Altraja and coworkers (1999) failed to show any reduction in Tn
expression in chronic asthmatics treated with the weak anti-inflammatory drug nedocromil
sodium, but found a reduction in Tn expression in patients treated with the ?2-agonist
albuterol. These authors hypothesized that the reduction in Tn expression may be derived
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from albuterol’s property of inhibiting the release of proinflammatory cytokines like
interferon ? and tumor necrosis factor ?.  In a recent study, Amin and coworkers
demonstrated that Tn layer thickness was increased parallel with lower epithelial integrity
in bronchial biopsy specimens from asymptomatic smokers compared with those from
asymptomatic never-smokers (Amin et al 2003). They also showed a significant
correlation between Tn layer thickness and eosinophils and mast cells in the bronchial
mucosa, which was not seen in asthmatic subjects (Laitinen et al 1997).  The role of Tn in
asthma has been studied in Tn-C-knock-out mice. That these mice were protected from
allergen-induced airway inflammation and goblet cell increase supports the view that Tn
plays an important role in asthma (Nakahara et al 2006).
1.3 Bronchial hyperresponsiveness and airway inflammation
BHR is a fundamental abnormality in asthma, representing both structural and
inflammatory changes in the airways due to the disease process. The chronic airflow
limitation due to airway remodeling forms a structural component which is irreversible.
The variable and potentially reversible component reflects the fact that an inflammatory
component of BHR may be reversed by treatment (Cockcroft and Davis 2006). Perhaps
BHR could be a surrogate marker for airway inflammation (Laprise et al 1999). However,
the causal relationship between BHR and airway inflammation is still unclear (Brusasco et
al 1998). Reports are conflicting concerning the relationship between inflammatory and
structural changes in the airways in asthma and degree of BHR (Table 1). One reason for
this may be the wide use of direct challenges to assess BHR: They are not as closely
correlated with airway inflammation as are indirect stimuli (Van Den Berge et al 2001,
Prosperini G et al 2002).
Anti-inflammatory treatment with inhaled corticosteroids reduces BHR markedly and
in parallel, it improves asthma symptoms (Juniper et al 1990), which supports the view
that BHR and inflammation may be associated. Treatment with inhaled corticosteroids
improves the structure of the damaged airway epithelium (Laitinen et al 1992) and reduces
the infiltration of inflammatory cells into the bronchial mucosa, a process which may be
linked to the reduction in BHR (Burke et al 1996, Boulet et al 2000). Sovijärvi et al (2003)
showed, in asthmatic subjects, that an inhaled corticosteroid, fluticasone 250 µg bid,
caused a very rapid attenuation of BHR. This same kind of rapid effect has been evident
with budenosine. A single dose of 2400 µg of budesonide has produced a 2.2-fold
improvement in BHR to hypertonic saline with a simultaneous significant reduction in
sputum eosinophils (Gibson et al 2001). However, even after long-term treatment with
inhaled corticosteroids and despite the absence of airway inflammation and reduced
epithelial damage, BHR persists (Lundgren et al 1988). Furthermore, the bronchial
biopsies obtained from healthy nonasthmatic subjects with BHR have shown no signs of
airway inflammation or remodeling (Power et al 1993).
Recent observations are that nerve growth factor (NGF) and other members of the
neurotrophin family may induce BHR in animals, and NGF appeared in BAL fluid from
asthmatic subjects (Frossard et al 2004).  Neurotrophins are produced by epithelial cells
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and inflammatory cells in the lung. Their expression is increased during allergic
inflammation, and they take part in the inflammatory process by prolonging the survival
of eosinophils (Hahn et al 2006).
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Table 1. Correlations between BHR to direct stimuli and histopathologic findings
in bronchial biopsies from asthmatic subjects.
Author (year) N Method Histologic variable correlation
with BHR
Roche et al 1989 8 PC20histamine BM thickening no
Jeffery et al 1989 21 PC20methacholine epithelial intergitya yes
Losewicz et al 1990 19 PC20methacholine epithelial damage nob
Foresi et al 1990 13 PC20methacholine cell infiltration in the epithelium yes
Djucanovic et al
1990
11 PC20methacholine eosinophil and mast cell numbers no
Ollerenshaw &
Woolcock 1992
10 PC20methacholine inflammatory cell numbers no
Ohashi et al 1992 19 PC20acetylcholine opening of tight junctions,
widening of intracellular spaces
yes
Bentely et al 1992 17 PC20methacholine eosinophil numbers yes
Ackerman et al
1994
28 PC20methacholine EG2+ cells, mast cells, CD3+ cells,
CD25 + cells
yes
Sont et al 1996 26 PC20methacholine eosinophils, mast cells, leukocytes,
CD8+ cells
yes
Cho et al 1996 13 PC20methacholine epithelial denudation, BM
thickness, inflammatory cell
numbers
yes
Roisman et al 1996 18 PC20methacholine eosinophil numbers noc
Chetta et al 1996 27 PC20methacholine inflammatory cell numbers in
epithelium, BM thickness
yes
Chetta et al 1997 34 PC20methacholine BM thickness yes
Boulet et al 1997 80d PC20methacholine subepithelial fibrosis intensity,
epithelial desquamation
noe
Crimi et al 1998 20 PD15methacholine inflammatory cell numbers no
Hoshino et al 1998b 25 PD15methacholine BM collegen III, collagen IV, and
tenascin
yes
Möller et al 1999 20 logPD20methacholine EG1+ and EG2+ cells, BM
thickness
no
Gibson et al 2000 20 PD20methacholine metachromatic cells (mast cells) yes
Milanese et al 2001 11 PD20methacholine BM thickness yes
van den Toorn et al
2001
37 PD20methacholine BM thickness and MBD density nof
Ward et al 2002 35 PD20methacholine BM thickness yes
Shiba et al 2002 36 PC20methacholine BM thickness yes
aPercentage of epithelium covering BM correlated positively with PC20 methacholine, bno difference in the epithelial structures
between normal subjects and asthmatics with BHR, ca significant negative correlation between eosinophils and PD15FEV1 to
bradykinin, d38 subjects were asthmatics, ea significant correlation between PC20methacholine and fibrosis found only in normoreactive
subjects, fa significant inverse correlation between PD20 AMP and BM thickness or MBP density.
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1.4 Bronchial hyperresponsiveness and asthma in athletes
1.4.1 Prevalence of bronchial hyperresponsiveness, respiratory symptoms,
and asthma in elite athletes
Several studies have reported a high prevalence of asthma, asthma-like respiratory
symptoms, and bronchial hyperresponsiveness accompanied by a frequent use of asthma
medication among highly trained competitive athletes (Weiler et al 1986, Larsson et al
1993, Heir and Oseid 1994, Mannix et al 1996, Sue-Chu et al 1996, Langdeau et al 2000).
The definition of asthma in these studies on athlete’s asthma varies: from self-reported
asthma to physician-reported asthma; diagnostic methods were also variable (Langdeau
and Boulet 2001). Especially endurance sports like long-distance running, cross-country
skiing, and swimming are associated with an increased frequency of asthma (Larsson et al
1993, Tikkanen and Helenius 1994, Potts 1996).  Atopy is a risk factor for developing
asthma in a normal population, but among endurance athletes, atopy increases the risk for
asthma substantially. Helenius and coworkers found that atopy, determined as at least one
positive skin test reaction, raised the risk for asthma in swimmers 96-fold compared to that
of nonatopic swimmers, who had a 6-fold higher risk for asthma compared with that of
control subjects (Helenius and Haahtela 2000). Asthma and exercise-induced
bronchospasm are common as well at the high-school level (Rupp et al 1992) and in
Olympic-level athletes (Voy 1986, Weiler et al 1998). Turcotte and coworkers (2003)
reported that nearly 50% of athletes suffer from exercise-induced symptoms.
BHR prevalence in athletes has been studied by several authors (Table 2), whose BHR
testing involved challenging the athletes to inhaled histamine or methacholine or to
hyperventilation of eucapnic dry air. The majority of the studies also included a sedentary
control group. The prevalence of BHR among the controls was lower than for the athletes.
Only a few studies showed any significant difference between athletes and controls.
Variability between studies and even within sports was great. BHR is frequent in athletes
with asthma-like respiratory symptoms but also in athletes without symptoms (Potts 1994,
Leuppi et al 1998). However, BHR to direct stimuli like methacholine is associated with a
higher risk for respiratory symptoms (Weiler et al 1986, Verges et al 2005).
The frequent use among cross-country skiers of anti-asthmatic drugs initiated a
discussion about whether cross-country skiing predisposes to asthma or whether athletes
use asthma medication to improve their performance. Questionnaire-based studies
confirmed that physician-diagnosed asthma in cross-country skiers is significantly higher
than in age-matched control subjects (Larsson et al 1994, Heir and Oseid 1994). Unlike in
the controls, asthma prevalence in the skiers increased with increasing age (Heir 1994).
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Table 2. Prevalence of BHR in athletes.
author sport N
(athletes)
N
(controls)
Prevalence
of BHR  in
athletes (%)
Prevalence
of BHR in
controls
(%)
Weiler et
al 1986
football/basketball 156/18 a 167 50/25 41
Larsson et
al 1993
cross-country skiing 42 a 29 79§ 10
Potts 1996 swimming 35 a 16 60 § 13
Sue-Chu
et al 1996
cross-country skiing 171 a NA 23 NA
Helenius
et al 1998a
swimming 29b 19 48§ 16
Helenius
et al
1998b
swimming/long-distance
running/ speed and power
42/71/49b 45 36§/9/18 11
Leuppi et
al 1998
basketball/ice hockey 50 a NA 21/35 NA
Langdeau
et al 2000
long-distance running +
biking,/cross-country
skiing+skating/triathlon/
swimming
25/25/25
/25 a
50 32/52/76/32§  28
Lumme et
al 2003
ice hockey 88b 47 24 11
Mannix  et
al 2004
high school athletes 79c NA 38 NA
Verges et
al 2005
cross-country
skiing/triathlon
29/10a 13 38/40 0
BHR methods: amethacholine provocation, bhistamine provocation, ceucapnic hyperventilation
§significant difference (P<0.05) between athletes and controls
1.4.2 Exercise-induced bronchoconstriction in athletes
When intense exercise causes bronchoconstriction, the phenomenon is called exercise-
induced bronchoconstriction (EIB) or exercise-induced asthma (EIA). EIB refers to
bronchial obstruction after provocation by exercise test or during self-induced exercise
even in the absence of a previous asthma diagnosis, and EIA infers symptoms induced
directly by exercise (www.wada-ama.org 2007). The bronchoconstriction is transient,
appears after cessation of the exercise, and it reaches its peak at 5-10 minutes after
exercise lasting from a few minutes to several hours. EIA is one symptom of asthma, and
the prevalence of EIA among asthmatics is high, ranging from 45 to 80% (Karjalainen
1991, Backer et al 1992, Bardagi et al 1993). Anti-inflammatory treatment attenuates but
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does not totally prevent EIA. Of asthmatic subjects treated with inhaled corticosteroids,
50% have shown EIA (Walkaans et al 1993).
EIB is common among athletes, prevalent even in athletes without an asthma diagnosis
(Rupp et al 1992, Mannix et al 1996, Schoene et al 1997). Its prevalence has been higher
in healthy nonasthmatic skiers than in control subjects, 35% vs 11% (Pohjantähti et al
2005). Atopy seems to enhance the possibility of an athlete’s reacting to exercise with
EIB. Helenius and coworkers showed that running in a cold environment caused EIB in
atopic but not in nonatopic elite runners (Helenius et al 1996). Post-exercise respiratory
symptoms do not predict EIB either in summer sports (Holzer et al 2002) or in winter
sports. Rundell and coworkers, comparing self-reported symptoms for EIA to postexercise
lung-function test results in 158 elite winter sport athletes, found that self-reported
symptoms yielded a high frequency of false positives and false negatives (Rundell et al
2001). Nor are self-reported symptoms reliable predictors of EIB in summer sports either
(Holzer et al 2002).
Exercise testing can be conducted in standardized laboratory conditions using a bicycle
ergometer or treadmill or outside the laboratory in field conditions. In the laboratory, EIB
is documented by measuring a fall of 10% in FEV1 (Sterk et al 1993), but in field
conditions a fall of 15% in FEV1 is required for diagnosis (Kukafka et al 1998).
Bronchial responsiveness to histamine or methacholine has low sensitivity but high
specificity for EIB (Holzer and Brukner 2004).  Deal and coworkers found that isocapnic
hyperventilation at rest can cause the same level of bronchoconstriction as does exercise
(Deal et al 1979). Currently, the most appropriate method to detect responsiveness to
exercise in athletes is eucapnic voluntary hyperventilation (EVH) (Anderson et al 2001,
Anderson et al 2003). But EVH is insufficiently accurate to detect EIB in every athlete at
risk. Mannix and coworkers (1999) compared EVH and exercise testing for 29 figure
skaters, demonstrating EIB in 16 skaters, but only 5 were positive in both tests; EVH
missed 4 skaters with EIB and exercise-testing performed at an ice-rink missed 7.
The main pathophysiological mechanism of EIB is heat and water loss from the airway
surface resulting in bronchospasm (Anderson and Daviskas 1997). Another theory of the
mechanism of EIB is the thermal theory (McFadden Jr 1990). It postulates that heat and
water loss from the airways during exercise leads to cooling of the airways followed by
rapid rewarming causing narrowing of the airways by hyperemia and vascular
engorgement.
The severity of EIB occurring in connection with specific exercise depends on level of
ventilation achieved and sustained during exercise and temperature and humidity of
inspired air (Deal et al 1979). At the beginning of exercise, air enters through the nose
where it is filtered, adjusted to body temperature, and humidified before it passes through
the trachea. During exercise, minute ventilation increases greatly; 140 to 150 l/min in
athletes (Stromme et al 2003) and even up to 200 liters in elite cross-country skiers (Rusko
2003). When minute ventilation exceeds 22 to 44 liters, a switch occurs from nose to
mouth breathing (Wheatley et al 1991), and the air-conditioning function of the nose is
lost. At least ten generations of airways are needed in the heating and humidification
process (Daviskas et al 1990). This leads to water loss from the liquid lining the airway
surface. The hyperosmolarity of this liquid due to water loss stimulates the release of
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inflammatory mediators such as histamine and leukotrienes, resulting in contraction of the
bronchial smooth muscle (Anderson and Holzer 2000). Inhaled mannitol induces
bronchoconstriction in an asthmatic subject most probably due to hyperosmolarity in the
airway surface liquid. The main mediator of hyperosmolarity-induced bronchoconstriction
is prostaglandin D2 derived from mast cells (Brannan et al 2006).
Reports are conflicting concerning EIA and airway inflammation in the asthmatic
population. Exercise challenge has not caused any increase in histamine or tryptase levels
or in inflammatory cells in BAL fluid in subjects with EIA (Jarjour and Calhoun 1992),
suggesting mechanisms other than histamine release by pulmonary mast cells as
responsible for EIA. Gavreau et al (2000) found that in ten asthmatic subjects with EIA,
exercise had no effect on inflammatory cells measured in blood or sputum, unlike with
allergen inhalation. Evidence does, however, support the inflammatory basis of EIB.
Venge and coworkers (1991) studied 13 asthmatic subjects with EIA and nine without;
only in subjects with EIA did exercise cause a small transient rise in serum eosinophilic
cationic protein (ECP), reflecting airway inflammation. These changes in ECP levels were
not associated with EIA severity. Crimi and coworkers (1992) showed that after exercise
challenge, more degranulating mast cells appeared in the bronchial mucosa, and a greater
percentage of eosinophils in the BAL than after methacholine challenge. In a recent study,
exercise challenge caused an increase in histamine, tryptase, and cysteinyl leukotrienes
levels in induced sputum (Hallstrand et al 2005).
The cause of this increased prevalence of EIB in athletes remains obscure despite
much research. Inhalation of large amounts of dry and often cold air during exercise may
cause an inflammatory reaction due to dehydration, leading then to EIB (Anderson and
Holzer 2000, Davis and Freed 2001). Environmental factors like temperature,
aeroallergens, air pollutants, and increased activity of the parasympathetic nerves may
contribute in athletes to development of EIB and BHR (Langdeau and Boulet 2001).
1.5 Cross-country skiing as a sport
Competitive cross-country skiing is an endurance sport requiring very high aerobic power
and capacity. The most important determinant of skiing performance is maximum oxygen
uptake (VO2max). In a trained adult skier weighing 72 kilograms, VO2max can be 87
ml/kg/min; in an unfit adult it is only about 30 ml/kg/min. In order to achieve this very
high level of oxygen uptake, top-level skiers need a high level of ventilation, which may
even reach 200 l/min or more. (Rusko 2003). Elite skiers’ exercise is very strenuous and
demanding. Oxygen consumption and need during heavy exercise is high, but the main
demand on ventilation is production of carbon dioxide (CO2) from the high energy
consumption. Heavy exercise is associated with metabolic acidosis resulting in a fall in
arterial pH. This requires a further increase in ventilation in order to recoup acidosis by a
compensatory decrease in arterial carbon dioxide tension (PCO2). (Stromme et al 2003) The
athlete must increase ventilation to achieve an acid-base balance resulting in hyperpnoea.
Ventilation is increased by increasing the depth (tidal volume) and frequency of breathing
until 70 to 80% of peak exercise performance, at which point ventilation is increased by
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frequency (Johnson et al 1992). Breathing frequency during ski-training or racing may
even reach 50 breaths per minute, which is very demanding for the humidification of the
air passing rapidly into the lower the airways, meaning that air reaching the lower airways
is dry and may actually cause lower-airway water loss. Highly trained athletes may
achieve the mechanical limits of their lung and respiratory muscles during maximal
exercise (Johnson et al 1992).
Elite cross-country skiers train intensively, with annual training hours ranging from
250 to 750 hours depending on age: Training hours increase with increasing age (Rusko
2003).  Training is not restricted to the Nordic snow season from the end of October till
April, as some training camps are at high altitudes. Weather conditions are cold (usually
with subfreezing temperatures) during ski-races and during part of the training season. As
temperature falls, air humidity also decreases, and at subfreezing temperatures the inspired
air is very dry.
1.6. Anti-asthmatic drugs – effects on airway inflammation and
bronchial hyperresponsiveness
Inhaled glucocorticosteroids have become the mainstay in the treatment of asthma.
Corticosteroids act mainly by binding to a glucocorticoid receptor in the cytoplasm of
various cells involved in the inflammatory reaction (Beato et al 1995). This steroid-bound
receptor translocates into the nucleus, binds to DNA glucocorticoid response elements,
and results in both suppression of inflammatory gene transcription and activation of anti-
inflammatory gene transcription (Barnes and Adcock 1998, Barnes 2006).
The introduction of the first inhaled corticosteroid, beclomethasone, caused a
revolution in asthma management in the early 1970’s (Clark 1972). At the moment,
several inhaled corticosteroids including beclomethasone, budesonide, and fluticasone are
available for clinical use in Finland. Long-term treatment with inhaled corticosteroids
improves both asthma symptoms and lung function and reduces BHR (Haahtela et al
1991, 1994, Sont et al 1999). Reduction in BHR is very rapid and can be reached in 3
days, but the effect tapers off within 2 weeks after cessation of treatment (Sovijärvi et al
2003). Inhaled corticosteroids are currently the most potent agents in the treatment of
airway inflammation in asthma, reducing inflammatory cell infiltration into the bronchial
mucosa and restoring the structure of the epithelium (Djukanovic et al 1992, Jeffery et al
1992, Laitinen et al 1992 Trigg et al 1994). This decrease in eosinophil numbers and T-
cell numbers may in part be due to apoptosis induced by corticosteroids (Druilhe et al
1998, O’Sullivan et al 2004). Corticosteroids have been shown to reduce the thickness of
the BM (Trigg et al 1994, Olivieri et al 1997, Hoshino 1998, Chetta et al 2003). However,
one study with a limited number of patients failed to show any changes in BM thickness
after short- or long-term treatment with budesonide (Jeffery et al 1992). Corticosteroids
inhibit microvascular leakage (Boschetto et al 1991), and some evidence shows that at
least high doses of inhaled corticosteroids reduce vascularity in asthmatic airways (Orsida
et al 1999, Chetta et al 2003). Treatment with inhaled corticosteroids reduces expression
of some inflammatory cytokines like GM-CSF and IL-8 (Wang et al 1994, Trigg et al
1994).
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Inhaled corticosteroids are safe to use; systemic side-effects are uncommon compared
with those from oral corticosteroids. The most common side-effects of are pharyngitis and
oral candiasis, caused by deposition of the drug in the oropharynx. However, high doses of
inhaled corticosteroids may exert the same systemic side effects as oral corticosteroids,
like hypothalamic-pituitary-adrenal-axis suppression, growth suppression in children,
osteoporosis, cataract, and skin thinning and bruising (reviewed by Dahl 2006).
?2-agonists have relieved asthma symptoms for more than four decades. Being potent
bronchodilators, they relax the bronchial smooth muscle by interaction with ?2-receptors,
which are abundantly present in the lungs (Nelson 1995). Furthermore, ?2-agonists
enhance mucociliary clearance (Devalia et al 1992), reduce vascular permeability (Erjefält
and Persson 1991), inhibit release of inflammatory mediators from mast cells (Butchers et
al 1991, Bissonnette and Befus 1997), eosinophils (Munoz et al 1994), and neutrophils
(Busse and Sosman 1984). They also inhibit cholinergic neurotransmission, resulting in
reduced cholinergic bronchoconstriction (Rhoden et al 1988). The principal side-effects of
?2-agonists are tremor, tachycardia, palpitations, and restlessness. Regular administration
of ?2-agonists may induce tolerance to their bronchodilator effect and may reduce
bronchoprotection (Nelson 1995, Ramage et al 1994).
Short-acting ?2-agonists are used as needed in asthma management to alleviate
asthma symptoms rapidly and therefore are known as the reliever medication. Salbutamol,
terbutaline, and fenoterol, the short-acting ?2-agonists available in Finland, are effective in
preventing exercise-induced bronchoconstriction (Godfrey and Konig 1976). The onset of
their action is rapid, and the duration of their effect is 3 to 6 hours (Nelson 1995). Regular
treatment with short-acting ?2-agonists is not recommended, because this can lead to
increased asthma exacerbations and BHR (Sears et al 1990, Taylor et al 1993), and worsen
airway inflammation (Manolitsas et al 1995).
Long-acting ?2-agonists formoterol and salmeterol have been in clinical use since the
1990’s and have longer duration of action (12 hours) than the short-acting ?2-agonists.
Adding a long-acting ?2-agonist to treatment for asthma not optimally controlled with
inhaled corticosteroids improves asthma symptoms, lung function, and BHR and reduces
asthma exacerbations (Greening et al 1994, Pauwels et al 1997, Lemanske et al 2001). As
monotherapy, long-acting ?2-agonists are less effective than inhaled corticosteroids in
reducing BHR or in controlling symptoms (Simons and Estelle 1997) and are
recommended only as add-on treatment with inhaled corticosteroids, not as monotherapy
(Lazarus et al 2001). The possible anti-inflammatory effects of long-acting ?2-agonists
have been investigated in only a few studies. In patients with mild asthma monotherapy
with salmeterol for 6 weeks significantly reduced the numbers of neutrophils in the
bronchial mucosa compared with fluticasone (Jeffery et al 2002). However, salmeterol
lacked this same anti-inflammatory effect for eosinophils or lymphocytes like fluticasone,
even though salmeterol treatment improved asthma symptoms and BHR better than did
flutacasone. Formoterol as monotherapy has reduced eosinophil and mast cell numbers in
the bronchial mucosa, but only in a subgroup of patients with higher baseline eosinophil
counts (Wallin et al 1999). Although one suggestion is that the bronchodilator effect of
long-acting ?2-agonists potentially masks airway inflammation (McIvor et al 1998), one
bronchial biopsy study comparing a high dose of fluticasone (500 µg bid) to salmeterol
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(50 µg bid) added to a low dose of fluticasone (200 µg bid) caused neither worsening nor
improvement in airway inflammation (Wallin et al 2003).
After allergen challenge, salmeterol inhibits the early and the late asthmatic reaction,
and inhibits the increase in serum ECP and EPX, suggesting an inhibitory effect on
eosinophil activation (Pedersen et al 1993). However, following bronchial segmental
allergen challenge, salmeterol failed to inhibit the inflammatory reaction at the bronchial
level (Calhoun et al 2001). Thus, the evidence of anti-inflammatory effects of long-acting
?2-agonists is weak (Openheimer and Nelson 2008).
Van Schayck and coworkers (2002) studied patient-perception of histamine-induced
bronchoconstriction during chronic dosing of salbutamol, salmeterol, and placebo, finding
no difference in the perception between the treatments and placebo. Asthma-related deaths
were earlier linked to the overuse of short-acting ?2-agonists (O’Byrne and Ädelroth
2006). Recent large trials have raised concern about the risk of deaths caused by long-
acting ?2-agonists (Nelson et al 2006, Salpeter et al 2006). At least part of the mortality
could be explained by the lack of inhaled corticosteroid treatment. Furthermore there is
extensive evidence that combining long-acting ?2-agonists with inhaled corticosteroids
reduces the risk for severe asthma exacerbations and hospitalization for asthma.
Combination inhalers of long-acting ?2-agonists and inhaled corticosteroids are
now widely used instead of separate inhalers. Combination inhalers are easier for the
patient and are at least as effective as the same agents from separate inhalers (Zetterström
et al 2001). Treatment with a combination of fluticasone and salmeterol (100 µg/50 µg
bid) compared with a higher dose of fluticasone alone (250 µg bid) for 24 weeks had a
similar effect on airway inflammation and remodeling (Jarjour et al 2006). Results from
recent in vitro studies suggest that combining long-acting ?2-agonists with corticosteroids
enhances corticosteroid anti-inflammatory action (Barnes 2006).
Antileukotrienes are targeted antiasthmatic agents that directly inhibit a group of
potent inflammatory mediators, cysteinyl leukotrienes, either by inhibiting the function of
leukotriene receptors (montelukast, pranlukast, zafirlukast) or by inhibiting their synthesis
(zileuton). The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are derivatives of the
metabolism of arachidonic acid known in the 1980’s as Slow-Reacting Substance of
Anaphylaxis (SRS-A) (Holgate and Dahlén 1997). Cysteinyl leukotrienes are potent
bronchoconstricting agents (Dahlén et al 1980) and cause mucosal swelling by increasing
vascular permeability (Rinkema et al 1984); they also cause increased mucus production
(Marom et al 1982). Cysteinyl leukotrienes are involved in the recruitment of
inflammatory cells, especially eosinophils, into the bronchial mucosa (Laitinen et al 2005).
Inhalation of LTE4 induced a significant bronchial constriction, and at the same time a
significant increase in eosinophils in the bronchial mucosa (Laitinen et al 1993b).
Antileukotrienes have a dual effect: anti-inflammatory and bronchodilating. They
improve asthma symptoms and lung function (Dahlén 2006) and also have
bronchoprotective properties to inhaled antigens and exercise (Currie and Lipworth 2002).
Montelukast is more effective in chronic treatment of EIB than is salmeterol because of its
sustained bronchoprotective efficacy (Villaran et al 1999). In a Japanese study, treatment
with pranlukast for 4 weeks reduced hyperresponsiveness to methacholine and also
reduced inflammatory cells in the bronchial mucosa compared with placebo (Nakamura et
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al 1998). However, O’Sullivan et al (2003) showed that combining montelukast with a
low dose of inhaled fluticasone had no additional effect either in reducing BHR to
methacholine or in reducing numbers of inflammatory cells in the bronchial mucosa. As
the clinical effects of antileukotrienes are inferior to those of inhaled corticosteroids, and
their role in asthma management is not fully established (Polosa 2007), they are used
mainly as add-on therapy to optimally control asthma. The advantages of antileukotrienes
are oral dosing and few side-effects, mainly headache and gastrointestinal discomfort
(Diamant and van der Molen 2005).
Cromones were introduced as a treatment for asthma in 1965 by Robert Altounyan,
who made the first experiments on himself, a sufferer from chronic asthma since
childhood (Edwards and Howell 2000).  Two cromones are available for the treatment of
asthma: disodium cromoglicate (DSCG) and nedocromil sodium, which are weak
antiinflammatory inhaled medications. They have no bronchodilator effect, but have been
shown to attenuate exercise-induced bronchoconstriction (Poppius et al 1970), reduce
BHR (Hoag and McFadden 1991, Anderson et al 1994, Fiocchi et al 1997), and improve
asthma symptoms. The mechanism of cromone action may be the blocking of chloride ion
channels (Heinke et al 1995). Treatment with DSCG reduces the numbers of inflammatory
cells and reduces expression of adhesion molecules at the bronchial mucosal level in
patients with atopic asthma (Hoshino et and Nakamura 1997). However, this study was
not blinded and was a single-agent study with no control group. Nedocromil sodium failed
to reduce either inflammatory cell counts (Altraja et al 1996b) or BM tenascin thickness
(Altraja et al 1999) in the bronchial mucosa of patients with chronic asthma. Compared
with inhaled corticosteroids, cromones are less effective and more costly (Andersson F et
al 2001). The advantage of cromones is their lack of significant side-effects, but they are
rather expensive compared with inhaled corticosteroids (Barnes et al 1995).
1.7. Diagnosis and treatment of asthma in elite athletes
To relieve asthma symptoms and achieve normal lung function, asthma in athletes should
be recognized and treated according to accepted guidelines (Bateman et al 2008), but
diagnosis of asthma in elite athletes is more complex than in a normal population (Weiler
et al 2007). Pulmonary function tests are often normal in athletes; in elite athletes,
diagnostic procedures for asthma should also include an exercise challenge test, preferably
in sport-specific conditions and environment, or EVH (Storms 1999, Anderson 2001).
An athlete may have chronic asthma from childhood, or symptoms of asthma may
develop during his/her career. Some athletes suffer from asthma symptoms induced only
by exercise (EIB). Major risk factors for an athlete’s developing asthma during an athletic
career are atopic disposition and training for an endurance sport (Helenius et al 2005). As
allergic rhinitis is common among athletes and is a risk factor for asthma, rhinitic athletes
should be screened for asthma (Bonini et al 2006). Allergic rhinitis in athletes needs
effective treatment (Helenius et al 2005). If an athlete has had chronic asthma since
childhood, management of the disease should follow normal guidelines. Regular use of
inhaled corticosteroids is the cornerstone of asthma management, and inhaled ?2-agonists
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when needed to treat or prevent bronchospasm. Leukotriene antagonists or chromones can
also be useful for an asthmatic athlete (Storms 1999). For those with chronic asthma,
symptoms of EIA may reflect poor asthma control (Weiler 2007), that should lead to
review of the athletes’ asthma management plan. Vocal cord dysfunction should be
considered as a differential diagnosis, if an athlete suffers symptoms like EIA despite
adequate asthma medication (Storms 1999).
When treating competitive athletes, physicians face the dilemma of doping regulations
and asthma medication. Competitive athletes need special approval from anti-doping
authorities to use asthma medications. The current list of prohibited and permitted
medicines can be checked at the web-site of the World AntiDoping Agency (WADA).
Inhaled ?2-agonists and glucocorticosteroids are prohibited substances. An athlete with
asthma may be authorized to take these medications, if he or she applies for a Therapeutic
Use Exemption (TUE) from the national anti-doping authorities (www.wada-ama.org).
TUE is valid for 4 years, but the treatment plan should be confirmed annually by a
respiratory physician. Currently, antihistamines, antileukotrienes, chromones,
anticholinergics, and theophylline are permitted without TUE, but use of inhaled steroids
and inhaled salbutamol, terbutaline, formoterol, and salmeterol require an abbreviated
TUE. Interestingly, immunotherapy is permitted (www.wada-ama.org).
Recently, athletes participating in the Olympic Games have been permitted to use ?2-
agonists only if they show objective documentation of asthma or EIB (Bonini et al 2004).
Otherwise the athlete applying for use of a ?2-agonist should fulfill one of the following
criteria: ? 12% increase in FEV1 (of the predicted FEV1 value) after the administration of
an inhaled ?2-agonist, ?10% fall in FEV1 in exercise challenge or in EVH, in
methacholine challenge PC20 < 4 mg/ml or PD20 ? 2 µmol in a steroid-naïve athlete or
PC20?? 6.6 mg mg/ml or PD20?? 13.6 µmol in athletes on inhaled steroids (Carlsen et al
2008). One non-medical treatment of EIB is a physical warm-up. It attenuates EIB in
athletes and is recommended also for non-athletic asthmatics before exercise (McKenzie
et al 1994).
1.7.1 Frequency of anti-asthmatic drug use among athletes
Asthma medication is frequently used by elite athletes (Heir et al 1994, Weiler et al
1996,). In the 1996 Summer Olympic Games, 15.3% of United States Olympic athletes
had a previous diagnosis of asthma and 13.5% had used asthma medication (Weiler et al
1998). A recent Finnish study reported increased use of any physician-prescribed
medication (Alaranta et al 2006). In a questionnaire sent to 494 athletes financially
supported by the Finnish National Olympic Committee and to age-matched controls.
34.5% of the athletes used some type of prescribed medication. The control group used
prescribed medication significantly less, 24.9% of respondents. In the athletic group, 7.0%
had been prescribed anti-asthmatic medication during the previous 7 days, and the
adjusted odds ratio for an athletic subject using asthma medication was 3.42.
Much concern has risen as to elite athletes using too much ?2-agonist, especially long-
acting ?2-agonists, to avoid increased risk for asthma exacerbations and asthma-related
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death (Sears 1990, Nelson et al 2006, Salpeter et al 2006). On the other hand, doubts exist
whether these enhance an athlete’s performance. This casts another shadow upon anti-
asthma medication, especially ?2-agonists. Despite ?2-agonists’ being the most commonly
used asthma medication among elite athletes (Weiler et al 1998, Helenius et al 2000).
1.7.2 Effects of anti-asthmatic drugs in athletes
Few studies examine the effects of antiasthmatic medicines in the management of asthma,
EIB, or asthma-like symptoms in elite athletes, with the ergogenic potential of anti-
asthmatic drugs studied more extensively. In a recent meta-analysis, Kinderman reviewed
19 randomized placebo-controlled trials on the ergogenic potential of ?2-agonists in non-
asthmatic athletes. He found no evidence that inhaled ?2-agonists could improve athletic
performance (Kinderman 2007).  Unlike the inhaled ?2-agonists, the oral formulations of
these drugs do possess ergogenic effects (Martineau et al 1992).
Treatment of symptoms or bronchoconstriction that occurs only in association with
exercise is not very well documented, and EIA in chronic asthmatics and athletes with EIB
differ (Weiler et al 2007). Inhaled ?2-agonists, both short-acting and long-acting, are
effective in preventing EIB in athletes (Ferrari et al 2000, Weiler et al 2007). Regular use
of short-acting ?2-agonists worsens EIB (Indman and O’Byrne 1996), and therefore cannot
be recommended. Daily use of ?2-agonists, especially without regular inhaled
corticosteroids, may lead to tachyphylaxis or partial loss of efficacy (Simons et al 1997,
Ramage et al 1994, Hancox 2002). ?2-agonists are also associated with the occurrence of
lymphoid aggregates in the bronchial mucosa of elite cross-country skiers (Sue-Chu et al
1998). Leukotriene antagonists are effective in preventing EIA in asthmatic subjects (Leff
et al 1998), but in a recent placebo-controlled study, montelukast failed to alleviate
asthma-like symptoms, BHR, or airway inflammation in highly-trained ice-hockey players
(Helenius et al 2004). The role of inhaled corticosteroids in treating EIB in athletes is not
well studied.
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2. AIMS OF THE STUDY
• To characterize airway wall inflammation in nonasthmatic ski athletes with
and without bronchial hyperresponsiveness and mildly asthmatic subjects
with bronchial hyperresponsiveness.
• To study tenascin immunoreactivity in the basement membrane zone in ski
athletes and compare the findings with  those of mildly asthmatic subjects
and control subjects
• To relate possible inflammatory changes to lung function, symptoms, and
bronchial hyperresponsiveness in ski athletes and in asthmatic subjects.
• To examine differences between airway inflammation in atopic and
nonatopic asthma.
• To evaluate the effects of budesonide treatment on airway inflammation,
basement membrane tenascin expression, and bronchial hyperresponsiveness
in non-asthmatic ski athletes with asthma-like symptoms and bronchial
hyperresponsiveness.
• To evaluate the effects of salmeterol, fluticasone, and disodium
cromoglygate on airway inflammation and tenascin expression in subjects
with newly diagnosed asthma and bronchial hyperresponsiveness.
• To study any differences between airway inflammation and bronchial
hyperresponsiveness in nonasthmatic elite ski athletes and subjects with
newly diagnosed asthma and chronic mild asthma
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3. MATERIALS AND METHODS
3.1 Subjects
The study population was composed of four groups: elite nonasthmatic cross-country
skiers (n=40) compared to subjects with mild asthma (n=12) and healthy nonathletic
subjects (n=12) (I). The fourth group of study subjects (n=79) comprised patients with
newly diagnosed asthma who participated in an intervention study comparing the effects
of salmeterol, fluticasone propionate, or disodium chromoglycate (III-IV). From the skier
group, subjects with bronchial hyperresponsiveness and respiratory symptoms (n=25)
were recruited to a drug intervention study comparing inhaled budesonide and placebo
(II).
None of these subjects had experienced any upper respiratory tract infection or asthma
exacerbation 4 weeks prior to investigational bronchoscopy. All subjects and parents of
those subjects younger than 18 years gave their written informed consent. The studies
were approved by the local ethics committees for the participating institutions.
3.1.1 Cross-country skiers (I-II)
The studies enrolled 44 competitive cross-country skiing athletes without prior diagnosis
of asthma from Sweden and Norway. They were attending senior secondary schools in
Norway and Sweden, or serving as conscripted soldiers in a Swedish military ski-platoon,
and were recruited to these studies while participating in an epidemiological study of
skiing and asthma (Sue-Chu 1996). All subjects with prior anti-inflammatory asthma
medication were excluded; 15% used inhaled ?2-agonists for respiratory symptoms. None
of the subjects was a current or former smoker. Their annual mean duration of training
was 434 hours (range 200 to 630). 30 skiers with BHR and asthmatic symptoms were
asked to participate in a drug intervention study (Study II), and 25 consented to do so.
3.1.2 Control subjects (I)
The control non-athlete subjects were 12 medical students (Tartu, Estonia), of whom 5
were female. Their mean age was 25 years (range 22 to 29 years). They had no current
respiratory symptoms or any allergy based on medical history and negative skin prick
testing. All were healthy non-smokers with normal lung function in spirometry without
abnormal reversibility in a bronchodilator test. PEF measurements showed no signs of
abnormal diurnal variation. No subject was involved in competitive sports.
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3.1.3 Mild asthmatics (I)
A total of 12 asthmatic subjects (Tartu, Estonia) with a well-documented medical history
and symptoms of asthma, 6 of them female, had mild asthma defined as forced expiratory
volume in one second (FEV1) >80 % of predicted. The asthma diagnosis was confirmed in
a bronchodilator test. Their asthma was considered chronic, because the diagnosis made at
least 2 years earlier. They underwent an at least 6-week break in anti-inflammatory asthma
medication before lung function testing and bronchoscopy. During this period asthmatic
symptoms were controlled with inhaled ?2-agonists or theophylline. All of these subjects
were nonsmokers.
3.1.4 Newly diagnosed asthmatic subjects (III-IV)
Patients with newly diagnosed, symptomatic asthma (diagnosis made within 2 years of
entering the study) aged between 18 and 60 were recruited in the regions of the Helsinki
University Central Hospital and North Karelia Central Hospital in Finland. Diagnosis of
asthma was according to guidelines of the American Thoracic Society (ATS) (American
Thoracic Society 1991) less than 2 years prior to entering the study. These criteria
included: at least 15% reversibility in FEV1, or at least 15% improvement in PEF, or at
least 20% diurnal PEF variation. These criteria were met either at entry to the study or 12
months earlier. Other inclusion criteria were: FEV1 60 to 100% of the national predicted
value (Viljanen et al 1982), moderate to severe bronchial hyperresponsiveness to
histamine (PD15FEV1 less than 0.4 mg) at entry (Sovijärvi et al 1993), either no smoking
history or  status of ex-smoker (less than 10 pack-years) for at least 2 years, no treatment
with long-acting ß2-agonists or cromones for 4 weeks, no antihistamines for 2 weeks, and
no inhaled or oral steroids for the last 2 months prior to the study. Subjects with
uncontrolled systemic disease, and women who were currently pregnant, lactating, or of
childbearing potential without adequate contraception were excluded. Patients with
seasonal allergies were not studied during the season for their allergy.  During 2 weeks
before the baseline bronchoscopy, all subjects recorded asthmatic symptoms (Table 3) and
PEF measurements on a diary card.
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Table 3. Asthma symptom scoring.
Daytime symptom score
0 no symptoms during the day
1 symptoms for one short period during the day
2 symptoms for two or more periods during the day
3 symptoms for the most of the day; symptoms did  not affect your normal daily
activities
4 symptoms for the most of the day; symptoms affected your normal daily
activities
5 symptoms so severe that you could not to go to work or perform normal daily
activities
Night-time symptom score
0 no symptoms during the night
1 symptoms causing you to wake once or wake up early
2 symptoms causing you to wake twice or more (including waking up early)
3 symptoms causing you to be awake for the most of the night
4 symptoms so severe that you did not sleep at all
3.2 Design of drug intervention studies
3.2.1 Skiers (II)
The study design was a double-blind, block randomized, placebo-controlled parallel-group
study. The 25 subjects were randomized to receive budesonide 400 µg or placebo twice
daily by Turbuhaler™ (Astra Draco AB, Sweden) for a planned 12 weeks. They were
skiers who were hyperresponsive and had asthmatic symptoms. Immediately before and
after the treatment period, each underwent fiberoptic bronchoscopies with bronchoalveolar
lavage (BAL) and bronchial biopsies. Bronchial hyperresponsiveness to methacholine was
also assessed before and after the treatment period.  At the end of treatment, each subject
was asked to evaluate the effect of treatment on respiratory symptoms. Compliance with
study medication was assessed by asking the subject if he or she had taken the medication
as instructed.
The study commenced in October/November 1993, which was prior to the start of the
competitive season. Practical problems made it impossible for the skiers to attend the
second bronchoscopy at 12 weeks after commencement of treatment, as this coincided
with the peak period of competition, so, in fact, the mean treatment period was 22 weeks
(range 10 to 32). During the treatment period, the subjects were allowed to use terbutaline
0.5 mg (Bricanyl Turbuhaler, Astra Draco AB, Sweden) as required.
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3.2.2 Newly diagnosed asthmatics (IV)
The study had a randomized, double-blind, double-dummy, placebo-controlled
parallel-group design. The patients visited the clinics (Helsinki University Central
Hospital and North Karelia Central Hospital in Finland) seven times. After a run-in period
of 2 weeks from the first visit, patients were randomized to receive inhaled salmeterol 50
µg (Diskhaler™) bid, fluticasone propionate 250 µg (Diskhaler™) bid, disodium
cromoglycate 5 mg (pMDI) four times daily (qid), or placebo for 16 weeks. When needed,
inhaled salbutamol pMDI 0.1 mg was allowed as rescue medication during the whole
study period. Bronchoscopy with bronchial biopsies was performed at baseline before
starting the study medication (visit 2) and after the 16-week treatment period (visit 6).
During the treatment period, the patients visited the clinic twice before the second
bronchoscopy (visits 3 to 5). Two weeks before each visit the patients recorded asthma
symptoms (Table 3) and PEF measurements on a diary card. After the second
bronchoscopy and cessation of treatment, the patients came to the clinic for a follow-up
visit (visit 7). Patients measured their morning PEF before taking their morning dose of
the study medication. At each clinic visit, compliance with study medication was assessed
by collecting and examining the inhalers and Rotadisks.
3.3 Investigation methods
3.3.1 Lung function tests and symptom evaluation
The skiers’ (I-II) lung volumes were assessed by spirometry with a Microlab 3300 Mk2 5
spirometer (Micro Medical Ltd., Rochester, UK).  The control subjects and mild asthmatic
subjects performed spirometry with Jaeger Flowscreen 2.1 gG spirometer (Erich Jaeger
Laboratories, Würtzburg, Germany).  In the patients with newly diagnosed asthma,
spirometry was measured with a Vitalograph spirometer (Fleisch, Bucks, UK). For the
control subjects, the bronchodilator test was performed with 3 x 0.2 mg inhaled rimiterol
(Pulmadil™, 3 M Health Care Ltd., Loughborough, UK) and for the asthma patients with
inhaled salbutamol (Ventoline™, Glaxo, London, UK).
In the skier group, bronchial hyperresponsiveness (BHR) was assessed with
methacholine by use of a controlled tidal volume breathing technique (Nieminen et al
1988). A cumulative dose of 1.8 mg methacholine was administered, and the test was
discontinued if a 20% fall in forced expiratory volume in one second (FEV1) occurred, and
the dose causing a 20% fall in (FEV1) was determined as PD20 FEV1. Subjects with PD20
FEV1?1.8 mg methacholine were considered to be hyperresponsive, as based on earlier
findings (Sue-Chu et al 1996). In all asthmatic subjects, BHR was assessed with histamine
challenge according to the method described by Sovijärvi et al (1993). A cumulative dose
of histamine causing a 15% fall in PD20 FEV1 was assessed. The subject was considered
as having severe BHR if the histamine dose was <0.1 mg, and moderate BHR at dose <0.4
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mg. Both methacholine and histamine challenges were performed with the Spira Elektro 2
inhalation-synchronized nebulizer (Respiratory Care Center, Hämeenlinna, Finland).
The skiers completed a questionnaire about respiratory symptoms (cough, wheeze, and
dyspnea at rest, during training, or at exposure to irritants), allergies, medical consultations
during the previous five years, use of antiasthmatic medication, smoking, training hours,
and competitive skiing experience (Larsson et al 1994). The questionnaire was in Swedish
or Norwegian depending on the subjects’ own language. The skiers suffering from wheeze
and abnormal breathlessness or chest tightness on exertion or at rest, or on exposure to
irritants during the previous year combined with bronchial hyperresponsiveness in
methacholine challenge were defined as having asthmatic symptoms.
Patients with newly diagnosed asthma completed diary cards to assess symptoms and
performed PEF measurements with a mini-Wright peak flow meter (Clement-Clarke,
Harlow, UK) twice daily during the 2 weeks of the run-in before bronchoscopy. In the
intervention study, each subject performed PEF measurements and assessed symptoms
during the 2 weeks before every clinic visit (IV). Asthma symptoms (0-5, daytime; 0-4
night-time) and number of puffs of rescue medication were recorded. In the intervention
study (IV), PEF measurements were performed before inhalation of the study drug. FEV1
and forced vital capacity (FVC) were measured with a Vitalograph™ spirometer (Fleisch,
Bucks, UK) at baseline. Histamine challenge was performed before noon at baseline
during the first clinic visit (III), and after 8 and 16 weeks of treatment (IV). The last
histamine challenge was performed 3 days before bronchoscopy at visit 6 (the day of the
second bronchoscopy). Efficacy of the treatment was measured as a change in reaction to
histamine challenge in doubling dose (DD) units.
3.3.2 Allergy testing and laboratory tests
Presence of atopy in the skier group (I) was tested with a Phadiotop CAP test (Pharmacia
Diagnostics, Uppsala, Sweden) which detects specific IGE in the serum to eight common
aeroallergens (birch, cat, cladosporium, dog, horse, house dust mite, mugwort, and
timothy). In control subjects and mild asthmatic subjects (I), the presence of allergy was
assessed with skin prick testing a panel of 12 common allergens (Soluprick SQ, ALK,
Denmark). In subjects with newly diagnosed asthma (Studies III-IV) atopy was assessed
by skin prick testing (Soluprick SQ) with a panel of ten common allergens in Finland
(alder, alopecus, birch, cat, horse, house dust mite, Kentucky blue, mugwort, reed,
timothy).
3.3.3 Fiberoptic bronchoscopy
Bronchoscopy and obtaining of bronchial specimens conformed to international guidelines
(Bleecker et al 1991).
The skiers (I,II) were premedicated with a solution of 2.5 ml salbutamol (1 mg/ml) and
1 ml ipratropium bromide (0.25 mg/ml) administered by nebulization at 15 minutes prior
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to bronchoscopy, followed by the intravenous administration of 0.3 to 0.5 mg
glycopyrronium, 1-2 mg midazolam, and 0.25 mg alfentanil. They were bronchoscoped
before the start of the skiing season in October and November at the University Hospital
in Trondheim. The skiers participating in the drug intervention study were bronchoscoped
the second time after the treatment period. Patients with mild asthma and control subjects
(I) were premedicated with intravenous atropine (0.5 to 1 mg) and oral diazepam (5 to10
mg). They were bronchoscoped at Tartu University Hospital. None of the subjects were
bronchoscoped during a respiratory infection or less than 4 weeks after one. The fiberoptic
bronchoscopy was performed under local anesthesia with topical lidocaine with the
Olympus BF XT20, BF IT30, and BT IT20D (Olympus Co., Tokyo, Japan). Bronchial
biopsies were performed at the first and second generation bronchial carinal levels from
both lungs.  The forceps were Olympus F-19C, FB-20C or FB-35C (Olympus Co).
In subjects with newly diagnosed asthma, fiberoptic bronchoscopy was performed
twice: before the start of the investigational medication (III) and after 16-week therapy
with the investigational medication (IV). Oral oxazepam 30 mg, intramuscular atropine
0.5 mg, and inhaled salbutamol 0.2 mg served as premedication. Lidocaine served as the
local anesthetic up to a maximum dose of 500 mg. The bronchoscope (Olympus BF
XT20) was introduced orally, and the biopsy specimens were taken with cupped forceps
(Olympus FB-36C E) from areas not yet touched by the bronchoscope at the lobar
bronchial level.
Macroscopic inflammatory index was assessed by an experienced bronchoscopist on a
five-point scale (0 to 4) (Van Vyve et al 1993). Friability, vascularity, and edema of the
bronchial mucosa, and amount of secretions in the airways were evaluated.
3.4 Examination of biopsy specimens
All bronchial biopsy specimens were snap-frozen in liquid nitrogen and stored at -70ºC
before processing. They were then embedded in Tissue Tek O.C.T. medium (Miles Inc.,
Elkhart, IN, USA), and 5-µm cryosections were cut on a Leitz 1720 Digital Cryostat
(Ernst Leitz GmbH, Wetzlar, Germany). The slides were coded and evaluated by the same
observer blinded to subjects’ clinical data or treatment.
Immunohistochemistry
Sections were stained with mouse monoclonal antibodies (mAbs) to detect inflammatory
cells by the alkaline phosphatase anti-alkaline phosphatase method, modified as reported
earlier (Laitinen et al 1997). The following mAbs were used: EG2 (Kabi Pharmacia
Diagnostic Ab, Uppsala, Sweden) to detect activated eosinophils (dilution 1:50); tryptase
clone AA1 (Dako A/S, Glostrup, Denmark) to detect mast cells (dilution 1:500); Ber-
Mac3 (Dako A/S) to detect macrophages (dilution 1:25); CD3+ (Dako A/S) to detect T-
lymphocytes; and neutrophil elastase clone NP57 mAb to detect neutrophils (dilution
1:2000). The sections were first fixed in acetone at room temperature (20oC) for 10
minutes, rinsed in Tris-buffered saline for 10 minutes, and then exposed to the primary
mAb for 30 minutes in a moist chamber. The rabbit anti-mouse immunoglobulin (dilution
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1:25, Dako A/S) and the mouse monoclonal antibody (dilution 1:25, Dako A/S) were
successively applied for 30 minutes. Following each antibody application, the slides were
washed in Tris-buffered saline. The color reaction was developed with New Fuchsin
(Sigma, St Louis, MO, USA). The endogenous alkaline phosphatase activity was blocked
with 1M levamisole (Sigma). For counterstaining, the sections were treated for 5 to10
seconds with Mayer’s hemalan (dilution 1:5, E. Merck, Darmstadt, Germany) and after
rinsing with water and distilled water, the slides were mounted with Glysergel (Dako A/S)
and cover-slipped. In Studies III and IV, eosinophils were detected by a different method:
The frozen sections were fixed with 4% paraformaldehyde in phosphate buffer at + 20oC
for 20 min, then exposed for 30 min to normal rabbit serum (dilution1:10) and then to
primary mAbs overnight at +4oC and processed for the avidin-biotin-peroxidase method in
accordance with manufacturer’s instructions (Vector Laboratories, Burlingame, CA,
USA). Negative controls and were provided by omitting the primary antibody and
replacing it with buffer. The slides were examined under Leitz Dialux 22 EB microscope.
The density of inflammatory cells in the entire sections was computed with the
Autocad program 10.1 (Autodesk Inc., Sausalito, CA, USA). The entire sections were first
photographed on Kodak Ektachrome EPN 100 color slide films at magnification of x16.
The slides were projected onto a calibrated 42x60-inch Kurta IS/THREE digitizing tablet
(Kurta Corp., Phoenix, AZ, USA). The total number of each inflammatory cell type was
counted with a pointing device throughout the bronchial mucosa, disregarding damaged
areas. The inflammatory cell counts were expressed as cells per mm2 of total mucosa
analyzed.
Tenascin expression in basement membrane
To detect the Tn immunoreactive area in the BM zone, the sections were stained with
mouse mAb 100EB2 (Locus Genex, Helsinki, Finland) (Balza et al 1993) by an indirect
immunofluorescence technique. The cryosections were first fixed in -20ºC acetone for 10
minutes and after being rinsed in phosphate buffer saline (PBS) the sections were
incubated for 30 min with the primary Mab in a moist chamber at room temperature. Then
sections were thoroughly rinsed in PBS and thereafter incubated in the same way as the
primary mAb with 1:150 diluted fluorescein isothiocyanate (FITC)-conjugated goat
antimouse IgG (Jackson Laboratories, Wets Grove, PA, USA). The sections were then
mounted in Veronal-glycerol buffer (1:1) pH 8.4 and cover-slipped. Negative controls
were provided by omitting the primary Mab or replacing it with an irrelevant one.
The specimens were examined with a Leitz Aristoplan fluorescence microscope
equipped with an appropriate filter. Areas containing crosssections of the immunoreactive
BM were photographed with Kodak T-MAX 400/800 black and white film (Eastman
Kodak Company, Rochester, NY, USA). Paper photocopies had a final magnification of
643. To quantitate Tn expression in the BM zone, the thickness of the Tn immunoreactive
area in the BM was measured from the photocopies semiautomatically by the
computerized image analysis Autocad program 10.1 (Autodesk Inc., Sausalito, CA, USA).
The upper and lower margins of the immunostained BM were digitized with a pointing
device; the mean distance (in micrometers) was regarded as thickness of the Tn in each
biopsy specimen.
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3.6 Statistical methods
In all studies, P-value <0.05 was considered statistically significant.
Data on cell counts and tenascin immunoreactivity thickness were in the skier baseline
study (I) analyzed by the Mann-Whitney U-test or Kruskal-Wallis test applying Dunn’s
correction for multiple comparisons. Correlations were calculated with Spearman’s rank
correlation method.
In the skiers’ intervention study, data underwent intention-to-treat analysis. To
evaluate differences between groups, the Kruskall-Wallis test with Dunn’s test was used.
Spearman’s rank correlation test was performed to evaluate any correlation between
inflammatory findings and pulmonary function tests.
Student’s T-test or the Mann-Whitney U-test served to assess comparisons between
atopic and nonatopic asthmatics (III). Correlation coefficients were calculated with
Spearman’s rank method when assessing the correlations between inflammatory cells and
tenascin immunoreactivity.
In the asthma intervention study, treatment effect on BHR was assessed by calculating
the doubling-dose effect, with logarithmic transformed PD15 values used. Testing of
significance of changes within groups during treatment was by Wilcoxon-rank sum tests.
Significance of the differences in the changes during treatment between the four groups
was tested with Kruskall-Wallis analysis of variance, and when appropriate, comparisons
were continued between groups. Diary card data were summarized over both the run-in
and the treatment period. Statistical analyses were performed with the SPSS package for
Windows (version 10). Means and standard deviations and range or 95% confidence
intervals (CI) were used in data presentation.
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4. RESULTS
4.1. Clinical characteristics of study subjects
Lung function in all study groups was on average normal (Table 4). This was in part for
safety reasons, because subjects with poor lung function (FEV1 <60% of predicted) were
excluded from the studies. Lung function was normal in skiers, mildly asthmatic patients,
and controls, with no significant differences between these groups. Skiers were
significantly younger than asthmatic subjects. All asthmatic patients were determined as
hyperresponsive by a histamine challenge test and fulfilled diagnostic criteria (ATS) for
asthma. They were mildly symptomatic before the investigational bronchoscopy. The
majority of skiers (75%) were hyperresponsive to methacholine. Asthmatic symptoms
were frequent among skiers, occurring in 26 subjects (65%). Six of the symptomatic skiers
reported use of an inhaled ?2-agonist. Asthmatic symptoms were slightly more frequent in
the hyperresponsive skiers than in nonhyperresponsive skiers (70% vs 50%); 18 skiers
reported wheeze, 14 reported dyspnea during training or competition, and only 11 of the
skiers were asymptomatic (unpublished data). Even though no exercise test was
performed, dyspnea during training or competition can be suggestive of EIB.
4.2 Inflammatory cells in bronchial biopsy specimens (I, III)
Adequate biopsy specimens were obtained from all skiers and mild asthmatics, but not
from all patients with newly diagnosed asthma. Neutrophil detection was impossible in the
control group, because of a lack of biopsy material from most of the control subjects.
In skiers, cell counts were greater than in the controls, T-lymphocytes by 43-fold
(P<0.001), macrophages by 26-fold (P<0.001), and eosinophils by two-fold (P<0.001).
However, in skiers, the increase in inflammatory cell densities did not quite reach that in
mildly asthmatic subjects, except for T-lymphocytes. Skiers had lower counts of
macrophages (P<0.001), mast cells (P<0.001), and eosinophils (P<0.001) than did mildly
asthmatic subjects. The T-lymphocyte count was higher than in controls in both skiers and
asthmatic subjects. T-lymphocyte counts were as high in skiers as in mild asthmatics. In
subjects with mild asthma, cell counts were significantly higher than in control subjects:
T-lymphocytes were increased by 70-fold (P<0.001), macrophages by 63-fold (P<0.001),
and eosinophils by 8-fold (P<0.001). No significant differences in mast cell counts
appeared between skiers and controls, but the mast cell count was 3-fold greater in
subjects with mild asthma than in controls (P<0.001) and 2-fold greater in subjects mild
asthma than in skiers.
The inflammatory cell counts in subjects with newly diagnosed asthma resembled
those in subjects with mild chronic asthma (Table 5). Neutrophil counts were significantly
higher in skiers than in mild asthmatics (P<0.05). Skiing experience in years correlated
43
positively with macrophage density in the bronchial mucosa (Rho=0.42, P=0.007), but not
with other cell densities.
Table 4. Clinical characteristics of study subjects.
Group Skiers
(n=40)
Mild asthmatics
(n=12)
Newly diagnosed
asthmatics
(n=80)
Controls
(n=12)
Gender
(men/women)
32/8 6/6 33/46 7/5
Age
(mean, range)
17.5
(16-20)
39.9
(18-58)
36
(18-61)
25
(22-29)
Presence of BHR
(n)
30 12 79 N.A.
BHR
(median ± SD)
1.25 µga
±  0.44
0.06 mg
±  0.15b
0.13 mg
± 0.1 b
N.A.
FEV1  % of predicted
±SD
99.2 ± 2.1 95.7 ± 3.22 80.9 ± 11.7 109.1 ± 4.52
FEV1 reversibility in
% ±SD
N.A. 29.34 ± 17.4 11.2 ± 8.8 5.39 ± 4.1
Duration of asthma
(years, range)
- 8.9
(2-30)
0.33
(0-2)
-
Presence of atopy
(%)
38 42 73 0
Study I, IIc I III, IV I
Degree of bronchial hyperresponsiveness determined by aPD20FEV1 to methacholine and
bPD15FEV1 to histamine. b25 of these subjects participated in Study II
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Table 5. Inflammatory cell counts as medians (interquartal range) in cells/mm2 in study
groups.
Cell type Skiers
(n=40)
Mild
asthmatics
(n=12)
Newly
diagnosed
asthmatics
(n=80)
Controls
(n=12)
Eosinophils 21
(9-52)
81
(61-119)
81b
(32,144)
10
(5-11)
T-lymphocytes 521
(315-972)
853
(557-1106)
409c
(271-725)
12
(0-44)
Mast cells 65
(43-95)
164
(89-226)
81c
(39-115)
50
(27-85)
Macrophages 105
(60-174)
253
(175-382)
204c
(115-301)
4
(0-9)
Neutrophils 83a
(47-119)
31
(10-68)
23c
(11-53)
N.A.
adata from 37 skiers, bdata from 71 subjects, cdata from 72 subjects
4.3 Tenascin in the bronchial biopsy specimens (I, III)
Tn immunoreactivity occurred in every skier and patient with asthma. In contrast to this,
the Tn immunoreactivity was absent from 50% of the control subjects. In control subjects,
Tn immunoreactivity showed as a thin and sometimes interrupted line underneath the
epithelium, whereas in the skiers and patients with asthma the immunoreactivity was
strong, showing as a distinct thick line underneath the epithelium. The Tn-specific
immunoreactivity band in the BM was significantly thicker in skiers [6.7 (IQr 5.3-8.5) µm,
P<0.001] and in mild asthmatics [8.8 (IQr 7.2-10.8) µm, P<0.001] than in controls [0.8
(IQr 0-3.1) µm] expressed as median and interquartile range. A significant increase in Tn
expression occurred in the order: controls < nonhyperresponsive skiers < hyperresponsive
skiers < mild asthmatics. Tn expression in mild asthmatics was greater than in skiers, with
no significant difference evident when comparing mild asthmatics with either
hyperresponsive or nonhyperresponsive skiers. No difference appeared in Tn
immunoreactivity between hyperresponsive and non-hyperresponsive skiers. Tn
immunoreactivity was present in every subject with newly diagnosed asthma, if adequate
biopsy material was obtained. The median Tn thickness in these subjects was 6.8 µm (IQr
5.9-8.3), markedly greater than in control subjects (Figure 1).
In skiers, tenascin immunoreactivity thickness did not significantly correlate with any
inflammatory cell type. In the group with newly diagnosed asthma, the thickness of the Tn
layer correlated positively with most of the inflammatory cell types studied except with
neutrophils and mast cells.
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Figure 1. Tenascin immunoreactivity band thickness in the bronchial basement membrane
(median).
4.4 BHR and airway inflammation in bronchial biopsy specimens
(I,III)
No difference in T-lymphocyte, macrophage, mast cell, and eosinophil counts emerged
between nonhyperresponsive and hyperresponsive skiers (Figure 2), showing that these
cells were not responsible for hyperresponsiveness in skiers. Compared to control
subjects, both hyperresponsive and nonhyperresponsive skiers had increased lymphocyte
(both P<0.001) and macrophage counts (both P<0.001), but eosinophil count was
significantly increased only in hyperresponsive skiers (P<0.001). Both hyperresponsive
and nonhyperresponsive skiers had lower counts of macrophages (P<0.05), mast cells
(P<0.05), and eosinophils (P<0.05) than did subjects with mild asthma. In the skier group,
none of the inflammatory cell densities were significantly correlated with PD20FEV1 to
methacholine.
For the patients with newly diagnosed asthma, we failed to show any correlation
between PD15FEV1 to histamine and any inflammatory cell density in their bronchial
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biopsy specimens. However, a significant negative correlation appeared between
eosinophil density and PD15FEV1 to histamine in a subgroup of atopic asthmatics (Rho=-
0.37, P=0.007), but not in nonatopic subjects (Rho=0.01, P=0.95). When blood
eosinophils and serum ECP were measured, neither eosinophils nor serum ECP correlated
significantly with FEV1 or PD15FEV1 to histamine.
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Figure 2. Density (cells/mm2) of macrophages, T-lymphocytes, mast cells, and
eosinophils in bronchial biopsy specimens from control subjects, skiers with and without
BHR, and asthmatic subjects. Horizontal bar=median value. The figure is reprinted from
Study I article with permission from Am J Respir Crit Care Med.
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4.5 Atopy and bronchial biopsy findings
Of the skiers, 16 (38%) were defined as atopic according to the Phadiotop CAP test.
However, only five subjects of those with a positive allergy test reported respiratory
allergies. Three Phadiotop-negative subjects reported allergic symptoms (unpublished
data). The densities of T-lymphocytes, macrophages, and eosinophils did not differ
between atopic and nonatopic skiers, but mast cell densities were higher in nonatopic than
in atopic skiers (P<0.01) (unpublished data). Comparing T-lymphocyte, macrophage, mast
cell, and neutrophil densities in the nonatopic skiers and nonatopic mild asthmatics
showed no difference, but eosinophil density was greater in nonatopic asthmatics than in
nonatopic skiers.
Among the subjects with newly diagnosed asthma, atopy was common: 58 (73%) had
positive reactions in the skin prick testing. No significant differences appeared between
nonatopic and atopic subjects for the inflammatory cell counts studied (T-lymphocytes,
CD8- and CD4-positive lymphocytes, macrophages, eosinophils, neutrophils, or IL4-
positive cells).
Tn immunoreactivity thickness was significantly greater in atopic than in nonatopic
subjects with newly diagnosed asthma, but with no significant difference between atopic
and nonatopic skiers (Figure 3).  In atopic subjects, thickness of the Tn layer correlated
positively with eosinophils, macrophages, and T-lymphocytes (including CD4- and CD8-
positive cells), whereas nonatopic subjects showed a positive correlation only with CD8-
positive cells. No correlation appeared with mast cells or neutrophils and tenascin.
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Figure 3. Tenascin immunoreactivity thickness in diagnosed the basement membrane
according to atopic status in skiers and in patients with newly asthma.
4.6. Treatment effects
4.6.1 The efficacy of inhaled budesonide in airway inflammation and BHR in
skiers
The skier treatment study involved 25 elite cross-country skiers: 12 treated with
budesonide and 13 with placebo. Mean duration (range) of the treatment period was
similar in both groups, in the budesonide group 22.3 (10 to 32) weeks and in the placebo
group 22.8 (20 to 27) weeks (P=0.78). One skier in the budesonide group withdrew from
the study at 10 weeks because he had experienced a worsening of his asthma-like
symptoms. The baseline characteristics between groups were similar except for PD20FEV1
to methacholine which was greater in the budesonide group (Table 6). Compliance was in
general good. Only two subjects (placebo group) reported moderate compliance, and the
rest reported themselves as showing good compliance.
Treatment with budesonide improved lung function (FEV1) significantly (P=0.005).
Responsiveness to methacholine improved in both treatment groups: It decreased in 10
skiers in the placebo group and in 9 skiers in the budesonide group; at the end of the
treatment period, BHR had disappeared in 7 skiers in each treatment group. No significant
changes were reported in asthmatic symptomsby skiers with good compliance. Asthmatic
symptoms worsened in 3 subjects in each treatment group, and improved in 2 subjects in
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the placebo group; and in 15 subjects symptoms neither improved nor worsened. The
macroscopic inflammatory index decreased in the placebo group but not in the budesonide
group.
Assessable paired pre-treatment and post-treatment biopsies were obtained from 11
subjects in the placebo group and 10 in the budesonide group. At baseline, their
inflammatory cell densities or Tn immunoreactivity thickness did not significantly differ.
There was no evidence of treatment effects. Neither inflammatory cell densities (CD3+
lymphocytes, macrophages, eosinophils, mast cells) nor Tn immunoreactivity thickness
(Figure 4) changed significantly within treatment groups (P varied between 0.06-1.0) or
between the two treatment groups after the treatment period (Figure 4).
Table 6. Clinical characteristics of study subjects.
Placebo N=13 Budesonide N=12
Males/females 9/4 10/2
Mean age (mean, range) 18 (16-20) 17.9 (16-20)
Training hours previous
year (mean ±SD)
468
(91)
427
(92)
Years of competition
(mean±SD)
8.3
(2.0)
7.5
(2.4)
FEV1, % of predicted
(mean)
93.1 95.9
PD20FEV1 methacholine
(mg)  (median, range)
1.1
(0.5-1.3)
1.5 *
(1.2-1.8)
Atopy 4 5
*P<0.05 compared with placebo group, Mann-Whitney U-test. Table is modified from
Study II article.
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Figure 4. Inflammatory cell densities (cells/mm2) in bronchial mucosa at baseline and at
follow-up. Figure reprinted from Study II article with permission of S. Karger AG, Basel.
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4.6.2 The efficacy of salmeterol (SLM), fluticasone propionate (FP), and
disodium cromoglycate (DSCG) in airway inflammation and BHR in newly
diagnosed asthma (IV)
In the run-in period of the study, 83 patients participated and 80 were eligible for the
treatment. One patient was excluded because of an upper respiratory infection at week 13.
Another patient was excluded because of an unexpected first epileptic seizure during the
treatment period. A total of 78 patients completed the study.
Symptoms and rescue medication use both during the night and day decreased in the
SLM, FP, and DSCG groups (P<0.036), but not in the placebo group. Morning PEF was
improved with both SLM and FP (by 46 and 75 L/min) (P<0.005) treatments. They also
improved lung function measured with FEV1 (by 0.23 L and 0.3 L, respectively)
significantly (P<0.005). BHR was improved significantly with SLM, FP, and DSCG, but
not with placebo. The doubling doses fromhistamine at the end of the treatment during
week 16 were 2.78 for SLM (CI 1.03 to 4.53), 5.22 for FP (CI 3.01 to 7.43), and 1.35 for
DSCG (CI 0.50 to 2.20) (all P<0.05). Placebo had no effect on hyperresponsiveness. The
doubling dose from placebo was 0.11 DD (CI –0.87 to 1.08). SLM was significantly more
effective than placebo (difference 2.67 DD CI 0.02 to 5.32, P=0.048). FP improved BHR
significantly more than did DSCG (difference: 3.87 DD CI 1.15 to 6.59, P=0.002) and
placebo (difference: 5.11 DD CI 2.39 to 7.83, P<0.001). The increase in doubling dose
was achieved at week 8 of treatment and was sustained at week 16 (Figure 5) (unpublished
data).
Figure 5. Doubling dose improvement from histamine at weeks 8 and 16 in salmeterol (SLM),
fluticasone propionate (FP), disodium cromoglicate (DSCG), and placebo (PL).
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Adequate paired biopsy material was obtained from 65 patients (5 to 6 specimens per
bronchoscopy). All subjects tolerated bronchoscopies well, and no complications occurred
during or after the bronchoscopy. Some subjects had hemoptysis just after the
bronchoscopy, but it disappeared in a few hours. Good-quality biopsy samples were not
available from all subjects. Representative samples for assessing inflammatory cell type or
Tn (BM area used for quantitation) ranged from 17 to 18 in the SLM group, from 12 to 16
in the FP group, from 18 to 19 in the placebo group, and was 18 in the DSCG group. At
baseline, no significant differences appeared in the cell counts, Tn immunoreactivity, BHR
to histamine, or lung function between treatment groups.
SLM had no significant effect on any cell type, and cell counts did not differ from
those of placebo treatment. Treatment with FP attenuated the eosinophilic inflammation
(Figure 6) by reducing EG2-positive cell counts (change –71 cells/mm2, CI -113 to -29,
P=0.002). FP also reduced CD3-positive T-lymphocytes, but this change did not reach
significance (change –274 cells/mm2, CI –587 to 40, P=0.060). DSCG also attenuated
eosinophilic inflammation by reducing eosinophil count significantly (change –54
cells/mm2, CI –127 to 18, P= 0.048). DSCG had no significant effect on CD3-positive
lymphocytes (change –182 cells/mm2, CI  408 to 44, P=0.248). No changes occurred in
any of the groups for mast cells or neutrophils (Table 7).
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Figure 6. Number of EG2-positive eosinophils in bronchial mucosa at baseline and after a 16-
week treatment with salmeterol (SLM), fluticasone propionate (FP), disodium cromoglycate
(DCG), and placebo (PL). The figure is reprinted from Study IV article with permission from
Elsevier.
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Table 7. Inflammatory cell counts (cells/mm2) in the bronchial biopsy specimens before and after
treatments.
Salmeterol
(n=17 )
Before         After
Fluticasone
propionate
(n=12 )
Before         After
Disodium
cromoglygate
(n=18 )
Before         After
Placebo
(n= 18)
Before         After
AA1 101.8
(77.5)
56.1
(54.3)
85.0
(54.2)
85.9
(72.5)
108.4
(88.4)
65.8
(39.8)
102.9
(97.3)
56.2
(38.4)
CD3 504.5
(394.0)
467.2
(300.7)
555.2
(344.2)
281.7
(267.2)
568.5
(527.5)
386.2
(196.4)
543.9
(391.8)
478.2
(296.8)
EG2 123.4
(114.6)
125.4
(144.4)
81.8
(72.0)
11.0a
(14.6)
120.6
(103.4)
66.2b
(104.1)
85.9
(77.4)
76.8
(82.4)
ELA 23.9
(16.6)
32.4
(25.3)
54.4
(64.6)
67.0
(46.8)
37.7
(31.9)
61.7
(55.6)
43.8
(40.9
43.9
(33.2)
Results are given as mean (with standard deviation). AA1 = mast cells, CD3 = T-lymphocytes,
EG2 = activated eosinophils, ELA = neutrophils are presented. aP=0.002, bP=0.048. The table is
modified from the Study IV article.
The macroscopic inflammatory index did not change significantly during any of the
treatments, but showed a tendency towards a decrease in mucosal erythema in the SLM
group and a decrease in mucosal edema in the FP group (Figure 7) (unpublished data).
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Figure 7.  Macroscopic evaluation by a bronchoscopist of mucosal oedema and vascularity  in
bronchoscopy before and after treatment. A five-point scale was used (0 to 4).
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5. DISCUSSION
5.1 Airway inflammation and remodeling in the bronchial
biopsies from elite cross country skiers
In this study we have shown an increased number of inflammatory cells, especially T-
lymphocytes and macrophages but also eosinophils and neutrophils, in bronchial biopsy
specimens from healthy young ski athletes with no prior diagnosis of asthma. We
anticipated that the number of inflammatory cells in the airways of the skiers would be
increased, but the magnitude of inflammatory cell densities was unexpected. We cannot
for certain exclude, among the skiers, the possibility of undiagnosed asthma. However,
none had a prior diagnosis of asthma made by a physician.  As EIB is prevalent among
athletics, testing for EIB by field exercise test or with EVH would have resulted in more
insights for the study (Rundell et al 2004, Parsons and Mastronarde 2005). Currently, to
receive permission for use of anti-asthmatic medication, the competitive athlete must show
evidence of reversible airflow obstruction or a 10% decrease in FEV1 in EVH or exercise
test. Evidence of nonspecific BHR is insufficient for diagnosis of asthma in elite athletes.
However, BHR is prevalent in athletes (Table 2), and asthma and respiratory symptoms
are common even in non-asthmatic athletes (Turcotte et al 2003). Studies investigating
inflammatory changes in the airways of athletes are small in number.
Helenius et al (1998a) reported increased numbers of eosinophils and neutrophils as
well as increased concentrations of EPO and human neutrophil lipocalin (HNL) in induced
sputum from asthmatic and nonasthmatic swimmers. They found no correlations between
BHR and sputum inflammatory indices. Furthermore, the nonasthmatic swimmers had
higher eosinophil counts and higher EPO and HNL in the sputum than did healthy
nonathelete controls. Bonsignore et al (2001) reported in healthy marathon runners
significantly raised neutrophil counts in induced sputum after a marathon versus baseline.
They found higher baseline neutrophil counts than in sedentary controls. Lumme et al
(2003), studying ice-hockey players, showed increased numbers of neutrophils and
eosinophils in the induced sputum of athletes compared with controls. They found no
correlation between BHR and sputum eosinophil counts. These findings are well in
keeping with our findings. We also found increased numbers of eosinophils and
neutrophils in the bronchial biopsy specimens of skiers. Unfortunately, we did not have
enough biopsy material to confirm the difference in neutrophils between controls and
skiers. However, the neutrophil count was significantly higher in skiers than in mild
asthmatics. This implies that the inflammatory reaction in skiers differ from that of
asthma. In contrast to findings in ice-hockey players (Lumme et al 2003) and swimmers
(Helenius et al 1998a), we found that eosinophil counts were higher in hyperresponsive
skiers. The eosinophil density was significantly lower in skiers than in asthmatics. This
also confirms a difference in inflammatory cell profile in skiers compared with asthmatics.
Verges et al (2005), studying airway inflammation and BRH in cross-country skies and
triathletes, found significantly higher eosinophil counts in hyperresponsive athletes than in
controls or athletes without BHR, which is in accordance with our findings. Interestingly,
58
in our study, numbers of macrophages and T-lymphocytes were higher than in controls,
but did not differ from those of mild asthmatics, which is a unique finding. Making direct
comparisons between bronchial biopsy studies and sputum studies is impossible, as
sputum induction is unreliable in investigating airway lymphocytes and macrophages
compared with bronchoscopy (Fahy et al 1995, Maesterelli et al 1995, Keatings et al
1997).
Like others (Helenius et al 1998a, Lumme et al 2003), we found no correlation
between degree of BHR and airway inflammation expressed as inflammatory cell
densities. Lymphocytes were observed to form special aggregates in the bronchial
biopsies, as reported earlier (Sue-Chu et al 1998). The ski athletes with BHR were more
symptomatic than were those without BHR, like athletes in the study by Verges et al
(2005). As athletes with BHR had more eosinophils in their sputum or bronchial biopsies,
it is possible that the symptoms could at least in part derive from eosinophilic
inflammation. However, what is confusing is that we saw distinct inflammatory cell
infiltration in the airways of even the asymptomatic and nonhyperresponsive skiers.
Tn expression in the airways of elite athletes has not been studied. We found increased
expression of Tn in the subepithelial basement membrane in skiers as well as in patients
with mild asthma compared with that of healthy controls. In contrast to findings in atopic
asthmatic subjects (Amin et al 2000), we found no difference between atopic and
nonatopic skiers. As Tn expression is considered to be a marker of remodeling in asthma
(Laitinen et al 1996, Laitinen et al 1997), its presence in the bronchial BM of skiers may
reflect injury followed by a repair process in the airways. That Tn expression did not
correlate with inflammatory cell counts suggests that there could exist some stimulus other
than inflammation causing epithelial injury that induces tenascin re-expression. At least
one of these stimuli may be hyperventilation of dry and usually cold air during strenuous
training and competitions.
5.2 Airway inflammation and remodeling in bronchial biopsies
from newly diagnosed asthmatics
We described inflammation in the bronchial mucosa of a large sample of subjects with
newly diagnosed asthma. Most of the subjects were steroid-naïve, and all had been on
solely rescue ?2-agonist treatment for at least 4 weeks before entering the study. One
important inclusion criterion was moderate or severe hyperresponsiveness, which made
the study group well defined. Comparing biopsy findings between studies is questionable,
because the methods quantifying inflammatory cells vary between bronchial biopsy
studies (Djukanovic 1996). The numbers of subjects in these studies are limited (usually
between 10 to 40) due to the invasiveness of the bronchoscopy.
We found eosinophil counts in subjects with newly diagnosed asthma similar to
eosinophil counts in subjects with seasonal asthma and in subjects with chronic asthma, as
did a study using the same quantification method (Laitinen et al 1997). This confirms that
eosinophils are important effector cells in various types of asthma. In accordance with
other studies (Laitinen et al 1996, Altraja et al 1999, Flood-Page et al 2003), we found
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distinct tenascin expression in the BM of the bronchial mucosa in every patient. Duration
of the disease in these subjects was short (mean duration only 0.33 years), so we can
presume that, in the pathogenesis of asthma, tenascin expression is upregulated very early.
5.3 Atopy and airway inflammation in newly diagnosed asthma
In the present study we were unable to distinguish atopic asthmatics from nonatopic
asthmatics by their bronchial mucosa inflammatory cell densities. This absence of
significant differences in inflammatory cell infiltration between patients with atopic and
nonatopic asthma was unexpected, since differences in the inflammatory mechanisms
have been reported (Humbert et al 1996, Menz et al 1998). Amin et al (2000) found
significantly more eosinophils and T-lymphocytes and significantly fewer neutrophils in
13 subjects with atopic asthma than in nine subjects with nonatopic asthma, which is not
in accordance with our findings. However, the present study with its markedly greater
number of patients failed to show differences in the inflammatory cell counts between
atopic and nonatopic asthmatics, leaving the concept of distinct inflammatory cell profiles
in these two phenotypes of asthma still vague.
In addition to counting cells in the airway mucosa, it is important to investigate the
presence of structural alterations in these asthma phenotypes. In the atopic asthma; airway
smooth muscle thickness is clearly increased (Amin et al 2005). The reason for ASM
thickening is unclarified, but mast cell-derived cytokines may enhance myofibroblast
differentiation into smooth muscle cells at least in allergic asthma (Gizycki et al 1996).
We studied the difference in BM composition between atopic and nonatopic asthma. A
difference appeared in Tn expression in the bronchial BM according to atopic satus. In
patients with atopic asthma, the Tn layer was significantly thicker than in patients with
nonatopic, in accordance with an earlier report (Amin et al 2000). In the present study, the
thickness of the subepithelial Tn correlated significantly with a wider range of
inflammatory cells including eosinophils, macrophages, and T-lymphocytes in the airway
mucosa in atopic asthma but not in nonatopic asthma, suggesting that Tn expression in this
asthma phenotype may be closely associated with the extent of the inflammatory process.
We found no correlation between mast-cell density and Tn thickness; such was found in
another study (Amin et al 2000) with a smaller number of subjects. The correlation
between eosinophils and Tn thickness in atopic asthma has been corroborated by others
(Flood-Page et al 2003). The association of macrophages and T-lymphocytes with Tn that
we found remains obscure. Although a problem may exist as to statistical power linked to
the smaller number of our nonatopic asthmatics compared to atopic asthmatics, our
association between Tn and major inflammatory cells may indicate more uniform
structural changes in atopic than in nonatopic asthma.
The mechanisms behind the up-regulation of Tn expression in the airways are mostly
unknown. TGF-ß and TNF-? induce Tn expression in cultured bronchial epithelial cells
(Linnala et al 1995, Härkönen et al 1995). In human atopic skin, a temporal relationship
emerged between the accumulation of eosinophils in the tissue and Tn up-regulation in
those fibroblasts which differentiated into myofibroblasts (Phipps et al 2002).  In atopic
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asthma, allergen challenge has been shown to cause an increase in Tn deposition in the
bronchial BM and a simultaneous increase in mucosal eosinophils and neutrophils (Phipps
et al 2004, Torrego et al 2007). TGF-ß can be found at increased levels in the BAL fluid of
asthmatic patients (Redington et al 1998). TGF-ß, which is produced by inflammatory
cells and structural cells in the airways, plays an important role in the immunomodulation
and fibrogenesis in asthma (Duvernelle et al 2003).
5.4 Effects of treatment in the intervention studies
5.4.1 Skiers
Unexpectedly, treatment with budesonide had no effect on airway inflammation or
symptom control either in hyperresponsive or in symptomatic skiers. The reason for lack
of symptom control may be lack of treatment effect, but the reason may also derive from
inadequate symptom recording. Symptoms were assessed based only on the skiers’
judgment, expressed after the treatment period. However, no difference in symptoms
during treatment appeared between the budesonide and placebo groups. Another weakness
of this study was compliance. This was assessed only by asking skiers whether they had
used their inhalers. A symptom diary and better compliance assessment would have
improved the quality of our study. As we found no significant clinical response, the lack
of differences in airway inflammatory changes after treatment between budesonide and
placebo groups was unsurprising. Budesonide treatment improves lung function (Haahtela
et al 1991) and airway inflammation in asthmatic patients (Laitinen et al 1992). In skiers,
budesonide improved lung function significantly, but did not attenuate airway
inflammation. The improvement in lung function indirectly indicates that the skiers
actually used the study medication. Why budesonide had no similar effect on airway
inflammation as it did in asthmatic patients remains obscure. We found a trend towards a
Tn immunoreactivity decrease in the budesonide group as evidence of some treatment
effect, even though the effect was not as distinct as seen in subjects with seasonal asthma
(Laitinen et al 1997). This effect on the BM may explain in part the improvement in FEV1
in the budesonide group.
In both budesonide and placebo groups BHR spontaneously improved. This may be
due to timing this study to the competition season. The training intensity was higher in the
autumn just before the beginning of the treatment and lower during the treatment period,
which coincided with the competition season. This theory is supported by another study
that reported variability in BHR in ski athletes in relation to changes in training intensity
(Heir 1994). BHR was highest during the most intensive periods of exercise. Timing of
the treatment study could explain the changes in BHR. In asthmatic subjects, budesonide
attenuates BHR, but the effect with adose of  800 µg daily is modest (Currie et al 2003).
We found no consistent effect of budesonide 400 µg bid on BHR. As the BHR was
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spontaneously attenuated in the placebo group as well, changes in BHR most probably
were not treatment-related.
No comparable studies examining treatment effects on airway inflammation in athletes
have been carried out, probably due to their invasive nature. All in all, studies
investigating the treatment effects of antiasthma drugs are few. Helenius and coworkers
(2004), did a placebo-controlled study with montelukast, a leukotriene modifier. Their ice-
hockey players suffering asthma-like respiratory symptoms showed, after 4 weeks of
treatment,  no effect on lung function, respiratory symptoms, exhaled nitric oxide, or
inflammatory indices in induced sputum. Thus far, no evidence has emerged for the
beneficial effects of anti-inflammatory treatment in athletes suffering from asthma-like
symptoms. However, studies on anti-asthma medication in athletes are sparse, being
mostly concentrated on possible doping-effects. Definite conclusions as to the
ineffectiveness of anti-inflammatory asthma medication in athletes with respiratory
symptoms thus cannot be drawn.
5.4.2 Newly diagnosed asthmatics
This present study compared treatment effects of SLM, FP, and DSCG with placebo in
asthmatic subjects with a short duration of the disease. All of the active treatments were
clinically effective; symptoms and need for rescue medication diminished. Only SLM and
FP improved lung function. The bronchoprotective properties against BHR of SLM, FP,
and DSCG have been demonstrated in other studies (Pedersen et al 1993, Nielsen and
Dahl 2000, Anderson et al 1994).
We found that FP was the most effective in improving BHR, exerting almost double
the DD effect of SLM. SLM has shown no bronchoprotective effect against adenosine-5’-
monophosphate (Soler et al 1994), suggesting the bronchoprotection of SLM probably
derives from direct action on the smooth muscle. In our study, the bronchoprotective
efficacy of SLM may be based merely on the bronchodilation caused by SLM taken in the
morning before histamine challenge.  The DD effect of DSCG was modest, and probably
not clinically significant. In the FP group, PD15FEV1 was normalized at 16 weeks of
treatment in six patients, but in no patient in the SLM group. The favorable treatment
effect of FP in BHR was not surprising, but the magnitude of DD effect was better than
reported earlier with a high dose (1000 µg bid) of FP (Booth et al 1995). However, these
results are not well comparable, as the authors reported the attenuation of BHR at
doubling dilutions (2.8). One explanation for the good response in BHR in the FP group
may be our patients’ short duration of asthma. BHR normalizes more frequently in
patients with short-duration than with long-duration disease (Boulet et al 2000).
We found no significant differences in the anti-inflammatory efficacy of the
treatments, perhaps due to the small numbers of subjects in the treatment groups. A
bronchial biopsy study is difficult and expensive to do with a large number of patients. We
gathered patients for 6 years to achieve the target number of 80 subjects. The statistical
power was calculated to be sufficient for analysis with this number. A within-group
decrease in eosinophils occurred in the bronchial mucosa in two treatment groups. FP 250
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µg bid had a relatively strong effect, and DSCG 5 mg qid had a moderate but also
significant effect against infiltration with EG2-positive eosinophils. Eosinophil reduction
with FP has been shown at a high dose (FP 1000 µg bid) and at a moderate dose (250 µg
bid) (Booth et al 1994, Olivieri et al 1997). We showed that DSCG, which currently in
clinical practice is mostly replaced by inhaled corticosteroids, has a significant anti-
eosinophilic effect. Our results for the anti-inflammatory effect of DSCG confirm the
results of another study, which was not placebo-controlled (Hoshino et al 1998c).
However, the treatment effect of DSCG in our study was less extensive than with FP. The
latter information, provided by the present study, may have an impact on the choice
between the two medications, since eosinophilia is regarded as the fundamental feature of
asthma (Jeffery et al 2000).
In contrast to other findings (Booth 1994, Olivieri 1997) we failed to show significant
effects on other inflammatory cells with FP. We saw a tendency toward a decrease in
CD3-positive T-lymphocytes, but this change was not statistically significant. In mast
cells, macrophages, or neutrophils, no treatment effect occurred. It is possible that our
dose of FP was too low. O’Sullivan et al (2002) showed that an FP dose of 500 µg bid was
more effective in treating airway inflammation than was 100 µg bid. They found a
significant reduction also in T-lymphocytes and macrophages not seen with a lower dose
(100 µg bid) of FP. At least part of the attenuation of BHR with FP and DSCG may be
explained by their effect on the reversible component of BHR and is thus associated with
improvement in airway inflammation (Cockcroft and Davis 2006).
Fear exists of detrimental effects of ?2-agonists on asthma (Salpeter et al 2006). We
demonstrated that treatment with SLM 50 µg bid as monotherapy administered for 16
weeks had neither a proinflammatory nor an anti-eosinophil effect on bronchial mucosal
inflammation in symptomatic patients with newly diagnosed asthma with BHR. Although
SLM exerted no significant anti-inflammatory effect, it proved to be a potent
bronchodilator and symptom-reliever. We found no anti-neutrophilic effect with SLM,
although such was evident in another study (Jeffery et al 2002).
The other currently available long-acting ?2-agonist, formoterol, has had some anti-
eosinophilic effect, but only in a subgroup of patients with mild asthma with higher
pretreatment eosinophil density in their bronchial mucosa (Wallin et al 1998). Thus far,
the results with SLM treatment do not confirm any anti-inflammatory group-effect of
long-acting ?2-agonists.  SLM combined with FP for one year has improved lung function,
asthma symptoms, and airway eosinophils in induced sputum with no signs of asthma
worsening (Koopmans et 2005). Furthermore, adding SLM (50 µg bid) but not adding FP
(100 µg bid) to regular inhaled corticosteroid treatment caused a significant reduction in
eosinophils in bronchial biopsies (Li et al 1999), but the possible harmful effect of long-
acting ?2-agonists on airway inflammation has not been ruled out. ?2-agonists may exert
some proinflammatory action. A combination of SLM and FP treatment led to increased
collagen and fibronectin deposition in the bronchial BM in rat model of allergen-induced
airway inflammation (Vanacker et al 2002).
An in vitro study demonstrated that the ?2-agonists isoproterenol and SLM blocked
corticosteroid-induced eosinophil apoptosis (Nielson and Hadjokas 1998). Regular
treatment with the short-acting ?2-agonist terbutaline raised sputum eosinophil counts in
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patients with mild or moderate asthma even when combined with corticosteroid treatment
(Aldridge et al 1999). McIvor et al (1998) showed that SLM attenuates asthma symptoms
and delays the recognition of asthma exacerbation, while at the same time eosinophilic
inflammation increases. The present study was too short in duration to find possible
treatment-caused asthma exacerbations. Loss of bronchoprotection against EIA or allergen
challenge may be a problem with chronic use of ?2-agonists, especially in asthmatics
exercising regularly (Ramage et al 1994, Nelson 1995).
We found no significant effects on the bronchial BM in any treatment arm. However,
the FP and DSCG groups showed a tendency towards decreased Tn expression in the BM.
A positive treatment effect in BM Tn has been shown with budesonide 400 µg bid in
patients with seasonal asthma (Laitinen et al 1997). Possibly a longer treatment period or
higher dose of FP could have induced significant changes in Tn, but the budesonide dose
used by Laitinen (1997) is comparable with the dose of 250 µg FP bid in the present study.
For the Altraja group (1999), treatment with nedocromil sodium had no effect on Tn
immunoreactivity in the BM, but treatment with the short-acting ?2-agonist albuterol
reduced Tn expression. Our long-acting ?2-agonist SLM had no influence on Tn
expression, and similarly Roberts and coworkers (1999) found no effects of SLM on
airway inflammatory cells in BAL or bronchial biopsy specimens, or in the depth of BM
collagen. A combination of FP and SLM (100/50 µg bid) had no effect on overall
thickness of BM (Jarjour et al 2006). Thus evidence exists that SLM would have an effect
on airway remodeling even when added to FP. In a recent report, treatment with Anti-IL-5
was effective in reducing Tn immunoreactivity thickness and density, and at the same time
reducing TGF-ß-positive eosinophils (Flood-Page et al 2003). This confirms that TGF-ß is
an important factor in Tn regulation.  However, more studies are needed to clarify
treatment effects on the ECM of BM.
5.5 Bronchial biopsy findings and bronchial
hyperresponsiveness
In the ski athletes we were unable to find any correlation between degree of BHR and
inflammatory cells or Tn in the bronchial BM. However, our skiers with BHR had a
slightly higher density of eosinophils in their bronchial mucosa. In the study of newly
diagnosed asthma, we found a significant correlation between degree of BHR and
inflammation only with eosinophil density in atopic asthmatics but no such correlation in
nonatopic asthmatics. The most consistent correlations between BHR and inflammatory
cell counts have been shown with eosinophil accumulation in the airways and the degree
of bronchial hyperresponsiveness measured with nonspecific stimuli like inhaled
methacholine (Woolley et al 1994, Chetta et al 1996, Gibson et al 2000). This association
of inflammatory cell counts and bronchial hyperresponsiveness has, however, remained
unclear (O’Byrne 1995, Power et al 1993).  Crimi and coworkers (1998) failed to show
any correlation between number of eosinophils in BAL or in bronchial biopsy specimens
and PD20FEV1 to methacholine, suggesting that other factors are mainly responsible for
airway hyperresponsiveness. Biopsy studies correlating inflammatory changes in BHR as
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measured by direct stimuli like histamine and methacholine have usually included rather
small numbers of subjects; measurement of inflammatory parameters differ greatly
between studies, making it difficult to draw firm conclusions. The present study
comprised a large number of patients compared with earlier numbers, but still we could
not confirm the association between eosinophilic infiltration and BHR.
In the general population, asymptomatic BHR is fairly common (19 to 62%) (Jansen et
al 1997) compared with the prevalence of asthma: 4 to 8% in Finland (Pallasaho et al
2005). Asymptomatic BHR may, however, still be a risk factor for development of
symptomatic asthma. Laprise and Boulet (1997), following 90 subjects with asymptomatic
BHR, found that the major risk factors for development of symptomatic asthma in this
population were genetic predisposition and, in sensitized subjects, exposure to allergen. In
one large-population study, BHR was an independent risk factor for asthma but also a risk
factor for chronic obstructive lung disease irrespective of atopy (Brutsche et al 2006). In
our study of nonasthmatic athletes, BHR was more common among atopic than among
nonatopic skiers.
Remodeling in the BM has been shown to correlate with BHR. We failed to show any
correlation between Tn layer thickness and BHR, either in the skiers or in asthmatic
subjects with a recent diagnosis.  Recently, Kariyawasam and coworkers (2007) studying
the effects of allergen challenge on BHR and inflammatory cells and BM content, found,
however, that allergen challenge caused an increase in BHR evident at 24 hours and at 7
days. They measured bronchial BM Tn and procollagen III expression and inflammatory
cell densities at the same time-points and found that Tn expression and inflammatory cell
densities returned to baseline at day 7, but procollagen III expression persisted. Their
results suggest that neither inflammatory nor Tn is important in persistent BHR, but
collagen expression in the BM may be.
The introduction of indirect measurements of BHR gives more possibilities to study
the variable component of BHR in asthma and to relate BHR to reversible airway
inflammation (Cockcroft and Davis 2006). Indirect challenges include physical stimuli
such as exercise and hyperventilation or chemical stimuli such as adenosine
monophospate (AMP) or mannitol. Bronchial provocation with AMP may be more
sensitive in reflecting airway inflammation (van den Berge et al 2001). The provocative
concentration of AMP causing a 20% fall in FEV1 correlated negatively with sputum
eosinophils as a surrogate marker of airway inflammation, whereas methacholine did not
correlate with markers of inflammation (Prosperini et al 2002). Furthermore, BHR to
mannitol correlates with airway inflammation as assessed by exhaled NO and eosinophils
in induced sputum (Pjorsbjerg et al 2007).
5.6 Possible explanations for airway inflammatory changes in
cross-country skiers
Why nonasthmatic skiers show inflammation in their airways is unknown. These
inflammatory changes in the airway mucosa may result from repeated airway irritation
from inhaling large amounts of dry, cold air during heavy exercise like training and
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competition. As temperature decreases, the humidity of the ambient air decreases
substantially (Houghton 1985), causing a decrease in humidity of the inspired air. In
skiers, BHR, asthma, and asthma-like symptoms persist even during summertime and after
the end of their competitive career (Larsson et al 1993, Verges 2004). In swimmers,
cessation of high-level training has caused attenuation of BHR and a decrease in sputum
eosinophils along with improvement in asthma symptoms. In some subjects, asthma even
disappeared (Helenius et al 2002). Swimmers who continued active swimming for 5 years
showed an increase in BHR and sputum eosinophils. Endurance training raises minute
ventilation substantially.
Skiing is a cold-weather sport, and much training and all competition takes place in a
cold environment. In dogs, repeated hyperventilation induces BHR and production of
inflammatory cells (eosinophils, neutrophils and macrophages) and leukotrienes (Davis
and Freed 2001). Alaskan racing sled dogs work in a very cold environment and therefore
have been considered a model of “ski asthma” (Davis et al 2002).  Bronchoscopic
examination of these dogs showed macroscopic inflammation and increased counts of
inflammatory cells compared with those in sedentary dogs. In another animal experiment,
Davis and coworkers (2005) found that in horses, exercise in subfreezing temperature led
to increased concentration of the TH2-type cytokines IL4, IL5, and IL10 in the BAL fluid
compared with leves during exercise in warm air. In humans, marathon racing raised the
plasma levels of the cytokines IL-10, IL8, and IL-1 receptor antagonist (Nieman et al
2001). IL-8 is a strong neutrophil chemotactic cytokine and may indicate neutrophil
activation during heavy exercise.  In healthy subjects, cooling of the facial skin causes
bronchoconstriction even while they are simultaneously breathing warm air (Koskela and
Tukiainen 1995). Skiers have their faces and whole bodies exposed to cold air, and
bronchoconstriction due to this exposure is possible, but not yet studied. Continuous work
in a cold environment for a long period (12 months) leads to increased respiratory
symptoms and BHR (Jammes et al 2002). These findings strengthen the theory that
exposure to cold air during hyperpnoea caused by strenuous physical exercise is mainly
responsible for the airway inflammation and BHR occurring in skiers.
Strenuous and prolonged endurance training leads to a transient decrease in the
immune defense, especially against respiratory viruses (Nieman 2000). Endurance athletes
like cross-country skiers are therefore at increased risk for respiratory tract infections. In
skiers, upper respiratory tract infections increase in BHR transiently when the subjects
continue training during the infection (Heir et al 1995). In sedentary controls, BHR does
not increase during the infection. Thus the increased frequency of respiratory tract
infections could also contribute to the BHR seen in our skiers.
Although strenuous exercise especially in cold air may be harmful for the airways of
athletes, it may have beneficial effects on nonathletic persons. In the European
Community Respiratory Health Survey II, frequency and duration of physical exercise
were inversely related to BHR (Shaaban et al 2007).  A 25-year follow-up of Finnish men
reinforces these findings. Pulmonary function decline was slowest in men who were in the
highest tertile in physically activity (Pelkonen et al 2003). The benefits of exercise and
physical training have been shown in nonelite long-distance runners. Scichilone and
coworkers (2005) showed that training attenuated BHR in nonelite long-distance runners.
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The runners in that study had better lung function than did sedentary controls. According
to a Finnish questionnaire study, recreational skiing did not lead to increased prevalence of
respiratory symptoms or obstructive pulmonary disease in subjects living in a cold
environment (Kotaniemi et al 2003). Indirect evidence arises from animal studies that low
and moderate aerobic exercise may reduce airway inflammation and remodeling (Vieira et
al 2007).
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6. PRACTICAL CONSIDERATIONS AND FUTURE
CHALLENGES
Asthma, BHR, and respiratory symptoms are common among elite athletes, and more
attention should be paid to studying the underlying reasons and possible treatments. At the
moment, asthmatic athletes are compelled to prove their asthmatic condition again and
again with objective lung function measurements in order to earn permission to use their
appropriate asthma medication during important international games like the Olympics
(Carlsen et al 2008). This sometimes leads to halting the anti-inflammatory medication in
order to show reversible airway obstruction or BHR, and this may lead to worsening of
their asthma. Regulations for the use of anti-asthma medication from the Medical
Commission of the International Olympic Committee have raised concern about asthma
management in athletes (Weiler 2003, Bonini et al 2004, Dickinson et al 2005). However,
the diagnostic change in FEV1 required in an exercise challenge, is smaller in athletes
(10%) than in nonathletic persons (15% according to ATS guidelines) (Carlsen et al
2008). Sports-induced respiratory disorders and chronic bronchial asthma in athletes
differ. Those athletes with chronic asthma should be treated according to international
asthma guidelines. Their treatment should be continuous, without interruption of their
anti-inflammatory treatment. No interruption in their treatment should take place only to
detect variable airflow obstruction for doping regulatory reasons.
The present study showed marked inflammation in the airways of nonasthmatic cross-
country skiers, inflammatory changes not predicted by lung function tests and induced by
the sport. Little is known about the course of the inflammatory reaction in the airways of
skiers during the years of their active racing career and afterwards. Longitudinal studies
are necessary to reveal what happens to the respiratory symptoms and lung function of
skiers over the course of time. Changes in respiratory symptoms and BHR may be
irreversible in skiers (Larsson et al 1993) as opposed to swimmers (Helenius et al 2002),
in whom airway inflammation and BHR was attenuated or even abolished after the end of
the active sports career. Noninvasive methods are less complex than bronchoscopy, and
biopsy can clarify the extent of airway inflammation among endurance athletes. Induced
sputum is one feasible method for assessing extent of inflammation (Helenius et al 2002,
Lumme et al 2003). Exhaled nitric oxide (NO) has been considered an indirect marker of
airway inflammation even in mild asthma (Ekroos et al 2002). It could serve as a useful
surrogate marker for airway inflammation in endurance athletes (Verges et al 2005), and
needs further studies.
Very few studies investigate anti-asthma medication in athletes suffering from
respiratory symptoms and airway inflammation induced by their sport. Studies with a
more detailed protocol are essential before rejection of inhaled corticosteroids or
antileukotrienes as useless medication in treating athletes’ airway disorders. It would be
intriguing to study effects of cromones in athletes: The present study of asthmatics showed
the antieosinophilic effect of DSCG. Both DSCG and nedocromil sodium inhibit
hyperosmolarity-induced bronchoconstriction and EIB including hyperpnoea-induced
bronchoconstriction (Anderson et al 1996). The use of a heat-exchanger mask may be
beneficial during exercise in cold air and thus also in cold-weather sports athletes. This
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mask warms and humidifies the inspired air. In asthmatic subjects, a heat-exchanger mask
can inhibit cold-induced bronchoconstriction at least as well as could the inhaled ?2-
agonist albuterol Beuther and Martin 2006). Effects of heat exchanger-masks should be
explored in skiers.
Duration of asthma before diagnosis seems to influence BHR. The shorter the time
from the onset of disease, the better the possibilities are to attenuate BHR (Haahtela et al
1994, Grönke et al 2002). It is possible to tailor asthma treatment using BHR assessment
as a tool to adjust the inhaled corticosteroid dose (Sont et al 1999).  This kind of tailoring,
aimed at reducing in BHR, was associated with fewer asthma exacerbations and better
lung function than with the reference strategy. The authors found that the strategy to adjust
the treatment to attenuate BHR was associated with a decrease in BM thickness. Thus
aiming treatment to reduce BHR may affect remodeling in the airways. The present study
revealed a tendency for FP to reduce the thickness of Tn in the BM in subjects with newly
diagnosed asthma. Simultaneously, BHR decreased significantly. However, using BHR
measurements in the follow-up of asthma is time-consuming and cannot be applied in the
asthma management plan of every asthmatic. Further investigations are necessary to
determine the usefulness of BHR in routine practice. We showed that DSCG caused a
modest decrease in BHR as well as a decrease in eosinophilic airway inflammation. The
anti-inflammatory effects of DSCG deserve more attention and further study.
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7. CONCLUSIONS
Marked inflammatory changes occurred in the bronchial mucosa of elite ski
athletes, both in hyperresponsive and nonhyperresponsive subjects. In skiers,
airway inflammation was less extensive than in mild asthma, but was
distinctly different from that of non-athletic control subjects. The
inflammatory cell pattern was different from that in asthmatic subject; it
showed a distinct neutrophilic cell infiltration but less extensive infiltration
of eosinophils, mast cells, and macrophages in bronchial biopsy specimens.
Inflammatory changes in the bronchial biopsy specimens from skiers were
unrelated to lung function or symptoms. Inflammatory changes were
apparent even in asymptomatic skiers.
In the skiers, tenascin expression was increased in the bronchial basement
membrane as a sign of remodeling, possibly reflecting bronchial epithelial
injury. Enhanced tenascin expression appeared in patients with mild
persistent asthma as well as newly diagnosed asthma.
Bronchial hyperresponsiveness showed no correlation with inflammatory
cell densities or tenascin expression in the bronchial mucosa.
Airway remodeling in atopic asthma differs from that in nonatopic asthma,
in which the injury-repair phenomenon seems to be less active because
tenascin expression is lower.
Budesonide failed to improve airway inflammation or tenascin expression in
the basement membrane in skiers. Bronchial hyperresponsiveness in ski
athletes varied in both the budesonide and placebo groups, possibly due to
training intensity, and was unrelated to airway inflammation, which
persisted.
Salmeterol treatment had no antieosinophilic effect on the airway mucosa in
patients with newly diagnosed asthma. Treatment with fluticasone
propionate or disodium cromoglicate attenuated the eosinophilic
inflammation in the airway mucosa in subjects with these patients. None of
these treatments reduced basement membrane tenascin expression.
These findings suggest that inflammation and BHR in skiers and asthmatic
subjects are of differing origins. Inflammatory cell pattern and response to
anti-inflammatory treatment differed. Treatment with inhaled corticosteroid
reduced BHR and improved lung function and respiratory symptoms in
asthmatic subjects, but not in the ski athletes. In ski athletes, strenuous
training combined with inhalation of large amounts of cold, dry air irritates
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the airways and may cause these distinct inflammatory changes in their
lower airways.
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